書籍詳細

未契約

書籍名	新女性医学大系 10 女性と感染症
出版社	中山書店
発行日	1999-02-28
著者	武谷雄二(総編集) 青野敏博(編集) 麻生武志(編集) 中野仁雄(編集) 野澤志朗(編集) 川名尚(担当編集)
ISBN	4521540910
ページ数	477
版刷巻号	第1版第1刷
分野	臨床医学：外科産婦人科学
シリーズ	新女性医学大系
閲覧制限	未契約

本巻では、感染のメカニズムや検査・診断・治療法等についてその全体像を俯瞰し、各論として性感染症、女性感染症、母子感染症を取り上げるほか、妊娠・分娩・産褥に及ぼす影響や周術期感染、院内感染等についても詳しく解説しました。病因、病態の最新知見から新しい診断法や治療法等まで、日常の臨床ですぐに活用できるよう各々疾患毎、病原微生物毎に、体系的にまとめました。感染症が女性に及ぼす影響をより広い視点から捉え直したこれからの産婦人科医に必携の書です。

表紙
閲覧
執筆者一覧
閲覧
目次
i閲覧
感染症総論
P.1閲覧
- I 感染症総論
- II 感染症の検査, 診断
- III 感染症の治療
- IV 手術と感染
感染症各論
P.85閲覧
- I 性感染症
- II その他の女性感染症
- III 感染症と妊娠, 分娩, 産褥
- IV 母子感染
- V 院内感染
Glossary
P.443閲覧
索引
P.451閲覧
- 和文索引
- 欧文索引
奥付
閲覧

参考文献

感染症総論

P.10 掲載の参考文献

1) Mandell GL, et al:Principles and Practice of Infectious Diseases, 4th ed, 1995, Dhuchell Livingstone, Edinburgh

2) Fields BN, et al (eds):Fields Virology. 3rd ed. 1996, Lippincott-Raven, Philadelphia

P.16 掲載の参考文献

1) Ogra PL, Mestecky J, Lamm M, et al:Mucosal Immunology, 2nd ed. 1998;Academic Press, San Diego

2) Kiyono H, Ogra PL, Mc Ghee JR:Mucosal Vaccines. 1996, Academic Press, San Diego

3) Kagnoff MF, Kiyono H:Essentials of Mucosal Immunology.1996, Academic Press, San Diego

4) 清野宏(編): 生体防御の最前線-粘膜免疫機構をめぐって. 別冊医学のあゆみ1996, 医歯薬出版, 東京

P.28 掲載の参考文献

1) Harrison SC, Sheel JJ, Wiley DC:Virus structure. Fields Virology, 3rd ed (Fields BN, Knipe DM, Howley PM, et al, eds). 1996;pp 59-99, Lippincott-Raven, Philadelphia

2) Tyler KL, Fields BN:Pathogenesis of viral infections. Fields Virology, 3rd ed (Fields BN, Knipe DM, Howley PM, et al, eds). 1996;pp 173-218, Lippincott-Raven, Philadelpia

3) Sharpe AH, Fields BN:Pathogenesis of viral infections:Basic concepts derived from the reovirusmodel. N Engl J Med 1985;312:486-497

4) Hierholzer JC, Killington RA:Virus isolation and quantitation.Virology Methods Manual (Mahy BWJ, Kangro HO, eds).1996;pp 25-46, Academic Press, London

5) Forghani B:Radioimmunoassay systems. Laboratory Diagnosis of Viral Infections, 2nd ed (Lennett EH, ed). 1992;pp 89-104, Marcel Dekker, New York

6) Forghani B:Enzyme immunoassay systems. Laboratory Diagnosis of Viral infections, 2nd ed (Lennett EH, ed).1992; pp 105-125, Marcel Dekker, New York

7) Oshiro LS, Miller SE:Application of electron microscopy to the diagnosis of viral infections. Laboratory Diagnosis of Viral Infections, 2nd ed (Lennett EH, ed). 1992;pp45-68, Marcel Dekker, New York

8) 古井敏行, 井村裕夫(監): 感染症. 臨床DNA診断法. 1995; pp918-994, 金原出版, 東京

9) Matsukura T, Sugase M:Identification of genital human papillomaviruses in cervical biopsyspecimens:Segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 1995;61:13-22

10) Yoshikawa H, Kawana T, Kitagawa K, et al:Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991;82:524-531

11) 青山友三, 南谷幹夫, 倉田毅(編): ウイルス感染症の臨床と病理. 1991, 医学書院, 東京

12) Iwasaki T, Sata T, Sugase M, et al:Detection of capsid antigen of human papillomavirus (HPV) in benign lesions of female genital tract sing anti-HPV monoclonal antibody. J Pathol 1992;168:293-300

13) Whitton JL, Oldstone MBA:Immune response to viruses. Fields Virology,3rd ed (Fields BN, Knipe DM, Howley PM, et al, eds). 1996;pp345-374, Lippincott-Raven, Philadelphia

14) Janeway CA, Travers P:Immunobiology:The Immune System in Health and Disease, 3rd ed. 1997;pp 9:1-52, Current Biology, London

15) 水谷裕迪: 血清学的立場から. ヘルペスウイルス感染症(森良一, 川名尚, 編). 1986; pp57-64, メディカルトリビューン, 東京

16) 川名尚, 本藤良: 型特異抗体測定法. ヘルペスウイルス感染症(森良一, 川名尚, 編). 1986; pp65-77, メディカルトリビューン, 東京

P.38 掲載の参考文献

1) Miller DL:A study of techniques for the examination of sputum in a field survey of chronic bronchitis. Am Rev Respir Dis 1963;88:473

2) 島川宏一: 泌尿・生殖器系, 消化器系材料の検体採取. 検査と技術 1996; 24: 50-52

3) 出口浩一: 日常診療に必要な臨床微生物学検査. 1995; p96, ユニオンエース, 東京

P.44 掲載の参考文献

1) 加藤延夫, 二宮敬宇: 嫌気性菌総論および嫌気性芽胞形成桿菌. 医系微生物学(加藤延夫, 編). 1987; pp156-163, 朝倉書店, 東京

2) 三鴨廣繁, 伊藤邦彦, 玉舎輝彦: 産婦人科領域における嫌気性菌, 特にPrevotella biviaについての臨床的意義に関する研究. 岐阜大学医学部紀要 1993; 42: 230-248

3) Larsen B:Normal flora and endogenous infections. Obstetric and Perinatal Infections (Charles D, ed). 1993;pp 3-9, Mosby, St Louis

4) Mikamo H, Kawazoe K, Tamaya T, et al:Comparative study on vaginal or oral treatment of bacterial vaginosis. Chemmotherapy 1997;43:60-68

5) 玉舎輝彦: 産婦人科領域感染症. 実地医家のための治療薬 1997; 2(2): 97-100

6) 玉舎輝彦: 産婦人科感染症. 産婦人科薬物療法のすべて. 1995; pp325-372, 金芳堂, 京都

7) 和泉孝治, 三鴨廣繁, 玉舎輝彦, ほか: 妊娠8ヵ月の腔内細菌叢の母児への影響について. 岐阜県母性衛生学会誌 1992; 8: 89-93

8) 玉舎輝彦: 細菌性膣症. 産婦人科治療 1992; 64: 84-88

9) 加藤直樹, 渡辺邦友: 偏性嫌気性菌. 臨床病理 1997; 105: 125-130

10) 渡辺邦友, 加藤直樹: 嫌気性菌の分離同定のポイント. Meedical Technology 1995; 23: 315-320

P.52 掲載の参考文献

1) 清水喜八郎: 感染症治療の理論的背景-抗菌薬投与理論を中心に. 日本産科婦人科学会雑誌 1991; 43: 815-823

2) 清水喜八郎(編): 抗菌薬治療マニュアル, 第3版. 1998, 日本臨牀社, 大阪

3) 清水喜八郎: 新・抗菌薬の使い方, 第4版. 1998, 三共

4) 長谷川裕美, 乙黒一彦, 清水喜八郎, ほか: VCMとCPRのMRSAに対するin vitro併用効果-postantibiotic phaseにおける抗菌効果. 感染症学雑誌 1996; 70(2): 151-160

P.58 掲載の参考文献

1) Donders GG, Moerman P, Caudron J, et al:Intra-uterine Candida infection:A report of fourinfected fetusses from two mothers. Eur J Obset Gynecol Reprod Biol 1991;38:233-238

2) Farmer C, Stanley MW, Bardales RH, et al:Mycoses of the breast:Diagnosis by fine-needle aspiration. Diagn Cypathol 1995;12:51-55

3) Arzeni D, Poeta DM,, Simonetti O, et al Prevalence and antifungal susceptibilty of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol 1997;13:447-450

4) Dismukes WE, Wade JS, Lee JY, et al:A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome.N Engl J Med 1990;323:1717-1723

5) Lynch ME, Sobel JD:Comparative in vitro activity of antimycotic agents against pathogenicvaginal yeast isolates. J Med Vet Mycol 1994;32:267-274

6) Kaplan B, Rabinerson D, Gibor Y:Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis. Int J Gynaecol Obstet 1997;57:281-286. fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995;172:1263-1268

8) Stein GE, Mummaw N:Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother 1993;37:89-92

9) Maenza JR, Merz WG, Romagnoli MJ, et al:Infection due to fluconazole-resistant Candida in patient with AIDS:Prevalence and microbiology. Clin Infect Dis 1997;24;28-34

10) Sanglard D, Kuchler K, Ischer F, et al:Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378-2386

11) Fong IW, Bannatyne RM, Wong P:Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis Genithourin Med 1993;69:44-46

12) Bolard J:How do polyene macrolide antibiotics affect the cellular membrane properties. Biochi m Biophys Acta 1986;64:257-304

13) Clemons KV, Stevens DA:Comparative efficacy of amphotoericin B collidal dispersion and amphotericin B deoxycholate supension in treatment of murine coccidiodomycosis, Atnimicrob Agents Chemother 1991;35:1829-1833

14) Hostetler JS, Clemons KV, Hanson LH, et al:Efficacy and safety of amphotericin B colloidaldispersion compared with those of amphotericin B desoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992:36:2656-2660

15) Tollemar J, Hockerstedt K, Ericzon BG, et al:Prophylaxis with liposomal amphotericin B (Am Bisome) prevents fungal infections in liver trasplant recipients:Long-term results of a randomized, placebo-controlled trial. Transplant Proc 1995;27:1195-1198

16) Bennett JE, Dismukes WE, Duma RJ, et al:A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-131

17) Horst CM, Saag MS, Cloud GA, et al:Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21
pubmed

18) Gillum JG, Johnson M, Lavoie S, et al:Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 1995;15:251-253

19) Lotholary O, Dupont B:Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997;10:477-504

P.66 掲載の参考文献

1) Zhou A, Paranjape J, Brown TL, et al:Interferon action and apoptosis are defetive in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J 1997;16:6355-6363

2) Gao WY, Johns DG, Chokekuchai S, et al:Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-didexynucleoside activities against replication of human immuno deficiency virus. Proc Natl Acad Sci USA 1995;92:8333-8337

3) Field HJ, Goldthorpe SE:Chemotherapy of herpes simplex virus infections:A laboratory perspective. Antiviral Chemotherapy (Jeffries DJ, De Clercq E, eds). 1995;pp127-154, John Wiley & Sons, New York

4) Haffey ML, Field AK:Selective inhibition of cyomegarovirus replication. Antiviral Chemotherapy (Jeffries DJ, De Clercq E, eds). 1995;pp 83-126, John Wiley & Sons, New York

5) De Clercq E, Holly A, Rosenberg l, et al:A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-467

6) Snoeck R, Bossens M, Parent D, et al:A double-blind, placebo-controlled study of cidofovir gel for human papilloma virus (HPV)-associated genital warts. Antiviral Res 1998;323:464-467

7) Niimura M:Intralesional human fibroblast interferon in patients with epidermodysplasia verruciforms. Herpes Viruses and Virus Chemotherapy (Kono R, Nakashima A, eds). 1984;pp313-324, Excerpta Medica, Amsterdam

8) Mitsuya H, Yarchoan R, Kageyama S, et al:Targeted therapy of human immunodeficiency virus-related disease. FASEB J 1991:5:2369-2381

9) Shirasaka T, Chodhichai S, Yamada A, et al:Comparative analysis of anti-human immunodeficiency virus type 1 activities of diexynucleoside analogs in resting and activated peripheral blood mononuclear cells Antimicrob Agents Chemother 1995;39:2555-2559

10) Gu Z. Salomon H, Cherrington JM, et al:K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1995;39:1888-1891

11) Shirasaka T, Kavlick MF, Ueno T, et al:Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving theraphy with dideoxy nucleosides. Proc Natl Acad Sci USA 1995;92:2398-2402

12) Larder BA, Kemp SD, Harrigan PR, et al:Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combiantion therapy. Science 1995;269:689-699

13) Wainberg MA, Drosopoulos WC, Salomon H, et al:Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-1284

14) Jonckheere H, Witvrouw M, De Clercq E, et al:Lamivudine resistance of HIV type 1 does not delay development of resistace to nonnucleoside HIV type 1-specific reverse transcriptae inhibitors as compared with wild-type HIV type 1. AIDS Res Hum Retroviruses 1998;14:249-253
pubmed

15) Tanaka M, Srinivas RV, Ueno T, et al:In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-fluoro-2',3'dideoxyadenosine. Antimicrob Agents Chemother 1997;41:1313-1318

16) Baba M, Shigeta S, Yuasa S, et al;Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 n vitro. Antimicrob Agents Chemother 1994;38:688-692

17) Piras G, Nakade K, Yuasa S, et al; Three-drug combiantion of MKC-443, Lamivudine and zidovudine in viro:Potential approach towads effective chemotherapy against HIV-1.AIDS 1997;11:469-475

18) Gulick RM, Mellors JW, Havlir D,et al:Treatment with indianavir,zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroval therapy. N Engl J Med 1997:337:734-739

P.73 掲載の参考文献

1) Points to Consider in the Design and Submission of Protocols for the Transfer of Recombinant DNA Molecules into One or More Human Subjects (現在は, Appendix M of GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT DNA MOLECULES, Effective June 24, 1994, Published in Federal Register, July 5, 1994 (59 FR 34496), Amendment Effective July 28, 1994, Federal Register, August 5, 1994 (59 FR 40170), Amendment Effective Apri 17, 1995, Federal Register, April 27, 1995 (60 FR 20726), Amendment Effective December 14, 1995, Federal Register, January 19,1995 (61 FR 1482), Amendment Efrective March 1, 1996, Federal Register, March 12, 1996 (61 FR 10004), Amendment Effective January 23, 1997, Federal Register, January 31, 1997 (62 FR 4782), Amendment Effective September 30, 1997, Federal Register, October 14, 1997 (62 FR 53335), Amendment Effective October 20, 1997, Federal Register, October 29, 1997 (62 FR 56196), Amendment Effective October 22, 1997, Federal Register, October 31, 1997 (62 FR 59032)). 1993

2) Points to Consider in the Human Somatic Cell Therapy and Gene Therapy. 1991

3) 遺伝子治療臨床研究に関する指針, 厚生省告示第23号. 1994

4) 遺伝子治療臨床研究に関するガイドライン, 厚生科学会議. 1993

5) Bunnell BA, Morgan RA:Gene therapy for infectious diseases. Clin Microbiol Rev 1998;11:42-46

6) Gunzburg WH, Salmons B:Virus vector design in gene therapy. Mol Med Today 1995;1:410-417

7) Becker Y, Darai G:Gene transfer by viral vectors for gene therapy. J Mol Med 1995;73:103-105

8) Miller AD, Miller DG, Garcial JV, et al:Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993;217:581-599

9) Miller DG, Adam MA, Miller AD:Gene transfer by retrovirus vectors occurs ony in cells that are actively replicating at the time of infetion [published erratum appears in Mol Cell Biol 1992;12:4331. Mol Cell Biol 1990;10:4239-4242

10) Miller AD:Retroviral vectors. Curr Top Microbiol Immunol 1992;158:1-24

11) Miller AD:Retrovirus packaging cells.Hum Gene Ther 1990;1:5-14

12) Gunzburg WH, Fleuchaus A, Saller R, et al:Retroviral vector targetting for gene therapy. Cytokine Mol Ther 1996;8;583-589

13) Kovesdi I, Brough DE, Bruder JT, et al:Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997;8:583-589

14) Kaneagae Y, Miyake S, Sato Y,et al:Adenovirus vector technology:An efficient method for constructing recombinant adenovirus and on/off swithching of gene expression. Acta Paediatr Jpn 1996;38:182-188

15) Miyake S, Makimura M, Kanegae Y, et al:Efficient generation of recobinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-lenght virus genome. Proc Natl Acad Sci USA 1996;93:1320-1324

16) Hallek M, Wendtner CM:Recombinant adeno-associated virus (RAAV) vectors for somatic gene therapy:Recent advaces and potential clinical applications, Cytokine Mol Ther 1996;2:69-79

17) Snoeck HW, Tao W,Klotman ME:Adeno-associated viral vextors:Background and technical aspects. Exp Nephrol 1997;5:514-520

18) Rolling F, Samulski RJ:AAV as a viral vector for human gene theray; Generation of recombinant viurus. Mol Biotechnol 1995;3;9-15

19) Muro Cacho CA, Salmulski RJ, Kaplan D:Gene tansfer in human lymphocyetes using a vector based on adeno-associated virus. J Immunother 1992;11:231-237

20) Thierry AR, Ravinoivch P, Peng B, et al:Characterrization of liposome mediated gene delivery:Expression, stability and pahmacokinetics of plasmid DNA. Gene Ther 1997;4:226-237

21) Gregoriadis G, Saffie R, de Souza JB:Liposome-mediated DNA Vaccination. FEBS Lett 1997:402:107-110

22) Felgner PL:Nonviral strategis for gene therapy. Sci Am 1997;276:102-106

23) Tomita N, Hiagaki J, Ogihara T, et al; A novel gene-tansfer techinique meiated by HMN(Sendai virus), nuclear protein, and liposome. Cancer Detect Prev 1994;18:485-491

24) Dzau VJ, Mannn MJ, Morishita R, et al:Fusigenic viral liposome for gene therapy in cadiouvascular disease. Proc Natl Acad Sci USA 1996;93:11421-11425

25) Poeschla E, Corbeau P, Wong-Staal F:Development of HIV vectors for anti-HIV gene therapy. Proc Ntl Acad Sci USA 1996;93:11395-11399

26) Dropulic B, Jeang KT:Gene therapy for human immunodefiecincy virus infection:Genetic antiviral stategis and targets or intervetion. Hum Gene Ther 1994;5:927-939
pubmed

27) Pomeratz RJ, Trone D; Genetic therapies for HIV infetions:Promise for the future. AIDS 1995;9:895-993

28) Caruso M, Klatzmann D:Selective killing of CD 4+cells harvoring a human immunodefieciency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci USA 1992;89:182-186

29) Caruso M, Bank A:Efficient retroviral gene transfer of a Tat-regulated herpes simplex virus thymidine kinase gene for HIV gene therapy. Virus Res 1997;52:133-143

30) Harrison GS, Long CJ, Curiel TJ, et al:Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum Gene Ther 1992;3:461-469

31) Schnell MJ, Johnson JE, Buonocore L, et al:Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997;90:849.857

32) Mebatsion T, Finke S, Weiland F, et al:ACXCR 4/CD 4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997;90:841-847

33) Galpin JE, Casciato DA, Richards SB:A phase I clinical trial to evaluate the safety and biological activity of HIV-IT(TAF) (HIV-1 IIIB env-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects. Hum Gene Ther 1994;5:997-1017

34) Haubrich RH, Flexner C, Lederman MM, et al:A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 1995;172:1246-1252

35) Haubrich R, Mccutchan JA, Holdredge R, et al:An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT(V) (HIV-1 IIIBenv/rev retroviral vector) in HIV-1-infected subjects. Hum Gene Ther 1995;6:941-955

36) Laube LS, Burrascano M, Dejesus CE, et al:Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Humn Gene Ther 1994;5:853-862

37) Donnelly JJ, Ulmer JB, Shiver JW, et al:DNA vaccine. Annu Rov Immunol 1997;15:617-648

38) Chatterjee S, Johnson PR, Wong KK Jr:Dual target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 1992;258:1485-1488

39) Chuah MK, Vandendriessche T, Chang HK, et al:Inhibition of human immunodeciency virustype-1 by retroviral vectors expressing antisense-TAR. Hum Gene Ther 1994;5:1467-1475

40) Morgan RA, Walker R:Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV 1 infected identical twins. Hum Gene Ther 1996;7:1281-1306

41) Duarte EA, Leavitt MC, Yamada O, et al:Hairpin ribozyme gene therapy for AIDS.tethodsmol Biol 1997;74:459-468

42) Yu M, Leavitt MC, Maruyama M, et al:Intracellular immunization of human fetal cord bloodstem/progenitor cells with a ribozyme against human immunodeficiency virus type l. Proc Natl Acad Sci 1995;92:699-703

43) Sarver N:Ribozymes:A new frontier in anti-strategy. Antisense Res Dev 1991;1:373-378

44) Dropulic B, Elkins DA, Rossi J, et al:Ribozymes:Use as anti-HIV therapeutic molecules.Antisense Res Dev 1993;3:87-94

45) Sarver N, Cantln EM, Chang PS, et al:Ribozymes as potential anti-HIV-1 therapeutic agents.Science 1990;247:1222-1225

46) Sullenger BA, Gallardo HF, Ungers GE, et al:Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990;63:601-608

47) Nakaya T, Iwai S, Fujinaga K, et al:Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein. Antimicrob Agents Chemother 1997;41:319-325

48) Bahne I, Kearns K, Hao QL, et al:Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol 1996;70:4352-4360

49) Lee SW, Gallardo HF, Gilboa E, et al:Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.J Virol 1994;68:8254-8264

50) Rondon IJ, Marasco WA:Intracellular antibodies(intrabodies)for gene therapy of infectious diseases.Annu Rev Microbiol 1997;51:257-283

51) Chen SY, Bagley J. Marasco WA:Intracellular antibodies as a new class oftherapeutic molecules for gene therapy. Hum Gene Ther 1994;5:595-601

52) Bird RE, Hardman KD, Jacobson JW, et al:Single-chain antigen-binding proteins. Science 1988;242:423-426

53) Huston JS, Levinson D, Mudgett-Hunter M, et al:Protein engineering of antibody binding sites:Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichiacoh. Proc Acad Sci USA 1988;85:5879-5883

54) Marasco WA, Haseltine WA, Chen SY:Design, intracellular expression, and activity ofa human anti-human immunodeficiency virus type 1gp120 single-chain antibody. Proc Natl Acad Sci USA 1993;90:7889-7893

55) Duan L, Bagasra O, Laughlin MA, et al:Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994;91:5075-5079

56) Wu Y, Duan L, Zhu M, et al:Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immuno deficiency virus type 1 rev:Variations in viral inhibition. J Virol 1996;70:3290-3297

57) Mhashilkar AM, Biswas DK, Lavecchio J, et al:Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.J Virol 1997;71:6486-6494

58) Levy-Mintz P, Duan L, Zhang H, et al:Intracellular expression of single-chain variable fragmentsto inhibit early stages of the viral life cycle by targeting human immunodeficiency virus typel integrase. J Virol 1996;70:8821-8832

59) Shaheen F, Duan L, Zhu M, et al:Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle.J Virol 1996;70:3392-3400

60) Maciejewski JP, Weichold FF, Young NS, et al:Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Natl Med 1995;1:667-673

61) Malim MH, Mccarn DF, Tiley LS, et al:Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.J Virol 1991;65:4248-4254

62) Malim MH, Freimuth WW, Liu J, et al:Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.J Exp Med 1992;176:1197-1201

63) Escaich S, Kalfoglou C, Plavec I, et al:Rev MIO-mediated inhibition of HIV-1 replication in chronically infected T cells. Hum Gene Ther 1995;6:625-634

64) Ragheb JA, Bressler P, Daucher M, et al:Analysis of trans-dominant mutants of the HIV type 1 rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. AIDS Res Hum Retroviruses 1995;11:1343-1353

65) Woffendin C, Yang ZY, Udaykumar, et al:Nonviral and viral delivery of a human immunodeficiencyvirus protective gene into primary human T cells. Proc Natl Acad Sci USA 1994;91:11581-11585

66) Modesti N, Garcia J, Debouck C, et al:Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.New Biol 1991;3:759-768

67) Green M, Ishino M, Loewenstein PM:Mutational analysis of HIV-1 Tat minimal domain peptides:Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.Cell 1989;58:215-223

68) Bahner I, Zhou C, Yu XJ, et al:Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993;67:3199-3207

69) Yu X, Yuan X, Matsuda Z, et al:The matrix protein of human immunodeciency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992;66:4966-4971

70) Trono D, Feinberg MB, Baltimore D:HIV-l Gag mutants can dominantly interfere with thereplication of the wild-type virus. Cell 1989;59:113-120

71) Lee PP, Linial ML:Inhibition of wild-type HIV-1 virus production by a matrix deficient Gagmutant. Virology 1995;208:808-811

72) Feinberg MB, Trono D:Intracellular immunization:Trans-dominant mutants of HIV geneproducts as tools for the study and interruption of viral replication. AIDS Res Hum Retroviruses 1992;8:1013-1022

73) Buchschacher GL Jr, Freed EO, Panganiban AT:Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum Gene Ther 1992;31391-397

74) Buchschacher GL Jr, Freed EO, Panganiban AT:Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant.J Virol 1995;69:1344-1348

75) 柊元巌, 神田忠仁: ヒトパピローマウイルスによるがん化機構. 最新医学 1997; 52: 67-73

76) 神田忠仁: HPVの発癌機構と子宮頸癌への関与. 産科と婦人科 1996; 63: 1211-1220

77) Madrigal M, Janicek MF, Sevin BU, et al:In vitro antigene therapy targeting HPV-16 E 6 and E 7 in cervical carcinoma. Gynecol Oncol 1997;64:18-25

78) He Y, Huang L:Growth inhibition of human papilloma virus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res 1997;57:3993-3999

79) Hamada K, Sakaue M, Alemany R, et al:Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells.Gynecol Oncol 1996;63:219-227

80) Alvarez-Salas LM, Cullinan AE, Siwkowski A, et al:Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.Proc Natl Acad Sci USA 1998;95:1189-1194

P.83 掲載の参考文献

1) 炭山嘉伸: 術後感染症の予防と対策. 産婦人科治療 1997; 74: 524-527

2) Hager WD:Postoperative infections:Prevention and management. Te Linde's Operative Gynecology,5th ed (Rock JA, Thompson JD, eds).1997;pp233-243, Lippincott-Raven, Philadelphia

感染症各論

P.100 掲載の参考文献

1) AIDS epidemic update:December 1998 WHO & UNAIDS

2) 鎌倉光宏: HIV感染症の疫学-海外・国内の動向. Mebio 1998; 15: 6-11

3) 清水勝, ほか: 一般集団におけるHIV感染のモニタリング. 平成8年HIV感染症の疫学研究班報告書. 1998; pp355-371

4) 熊本悦明: 本邦におけるAIDS/STD流行の現状. 第2回SRL感染症フォーラム講演集. 1997; pp23-37

5) 熊本悦明: HIV/AIDSは今やSTDである-STDとはHIV/AIDSとの関連性. INFECTION CONTROL 1997; 6: 516-521

6) 熊本悦明, 塚本泰司, 岩澤晶彦: クラミジアの陰にエイズあり-従来のSTDとHIV感染との関連性. 臨床と微生物 1997; 24: 387-396

7) Wasserheit JN:Epidemiological synergy:Interrelationship between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;19:61-77

8) Grosskurth H, Mosha F, Todd J, et al:Impact of improved treatment of sexually transmitted disease on HIV infection in rural Tanzania:Randomised controlled trial Lancet 1995;346:530-536

9) CDC:Sexually transmitted diseases surveillance 1996

10) 三井幸彦: 子宮トラコーマ. 日本眼科全書, 16巻, 結膜疾患(日本眼科学会, 編). 1955; p63, 金原出版, 東京

11) 熊本悦明: 性のある所, 感染あり-HIV感染/性感染症の流行の現況. 治療学 1997; 31: 796-813

12) 熊本悦明: わが国における性感染症の現状と問題点. 臨床検査 1996; 40: 631-637

13) 熊本悦明: 7 モデル県におけるSTDセンチネル・サーベイランス報告(厚生省班研究, 班長熊本悦明) 1998年

14) Iwasawa A:Studies on human papilloma virus in urogenital lesion. 1994;63:35-51

15) 前田信彦, 南邦弘, 熊本悦明, ほか: 妊婦におけるHPV, クラミジア, 淋菌感染症の実態調査. 第11回日本性感染症学会. 1998年12月

16) 南邦弘, 熊本悦明, ほか: 子宮頸癌患者年齢分布と悪性HPV感染の検討. 第11回日本性感染症学会. 1998年12月

P.106 掲載の参考文献

1) 大阪府環境保健部: 平成8年度大阪府における性感染症動態調査概要. 1997; pp19-21

2) 大阪府立万代診療所: 未発表データ.

3) 厚生省: 伝染病統計. 昭和25年～平成6年.

4) Johnston NA:Neonatal congenital syphilis:Diagnosis by the absorbed fluorescent treponemal antibody (Igm) test. Br J Vener Dis 1972;48:464-469

5) Dorfman DH, Glaser JH:Congenital syphs presenting in infants after newborn period.N Engl J Med 1990;323:1299-1302

P.114 掲載の参考文献

1) Kamal H:A Dictionary of Pharonic Medicine.1967;National Publication House, Cairo, Egypt

2) Ricord PH:A Practical Treatise on Venereal Disease,2nd ed.1838

3) Kampmeire RH:Identification of the gonococcus by Albert Neisser. Sex Transm Dis 1978;5:71-72

4) 厚生省保健医療局エイズ結核感染症課: 平成9年度感染症サーベイランス事業年報.

5) Sexually Transmitted Disease Surveillance 1996. Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta

6) Mc Gee ZA, Johnson AP, Taylo-Robinson D:Pathogenic mechanisms of Neisseria gonorrhoeae:Observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 1981;143:413-422

7) Easmon CSF,Ison CA:Neisseria gonorrhoeae:A versatile pathogen.Clin Pathol 1987;40:1088-1097

8) Blake MS, Gotschlich EC:Gonococcal membrane proteins:Speculation on their role in pathogenesis. Progr Allergy 1983;33:298-313

9) Gregg CR, Johnson AP, Taylo-Robinson D. et al:Host species-specific damage to oviduct mucosa by Nisseria gonorrhoeae lipopolysaccharide. Infect Immun 1981;34:1056-1058

10) Mulks MH, Plaut AG:Ig A protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae.V Engl J Med 1978;299:973-976

11) Westrom L, Mardh PA:Pelvic inflammatory disease:Epidemiology. diagnosis, clinical manifestations, and sequelae. International Perspectives on Neglected Sexually Transmitted Diseases (Holmes KK, Mardh PA, eds).1983;pp235-250, Hemisphere Publishing, New York

12) Svensson L, Mardh PA, Westrom L:Infertility after acute salpingitis with special reference to Chlamydia trachomatis. Fertil Steril 1983;40:322-329

13) Hook EW, Holmes KK:Gonococcal infections. Ann Intern Med 1985;102:229-243

14) Barlow D, Phillips I:Gonorrhea in women:Diagnostic. clinical, and laboratory aspects. Lancet 1978;i:761-764

15) Eshenbach DA, Buchanan TM, Pollock HM, et al:Polymicrobial etiology of acute pelvic inflammatory disease.V Engl Med 1975;293:166-171

16) 小島弘敬: 淋菌感染症. 性と感染(STD)性感染症学(熊本悦明, ほか編). 1990; pp121-136, 医薬ジャーナル社, 大阪

17) 小島弘敬: 淋疾. 泌尿器科 MOOK 1, 尿路・性器感染症(熊澤淨一, 編). 1992; pp168-182, 金原出版, 東京

18) Zenilmam JM:Atlas of Infectious Diseases, Vol 5, Gonorrhea, Sexually Transmitted Disease(Mandell GL, Rein MF, eds).1996;p 24, Churchill Livingstone, Philadelphia

19) Handsfield HH, Lipman TO, Harnisch JP, et al:Asymptomatic gonorrhea in men:Diagnosis,natural course, prevalence, and significance.V Engl Med 1974;290:117-123

20) 田中正利, 熊澤淨一: 淋菌感染症の検査法の適用とその読み方. 日本性感染症学会誌 1992; 2: 28-35

21) Ho BSW, Feng WG, Wong BKC, et al:Polymerase chain reaction for the detection of Neisseriagonorrhoeae in clinical samples. J Clin Pathol 1992;45:439-442

22) Stary A, Ching SF, Teodorowicz L, et al:Comparison of ligase chain reaction and culture for detection of Neisseria gonorrhoeae in genital and extragenital specimens.Clin Microbiol 1997;35:239-242

23) Hook EW, Ching SF, Stephens J, et al:Diagnosis of Neisseria gonorrhoeae in actions in women by using the ligase chain reaction on patient-obtained vaginal swabs.Clin Microbiol 1997;35:2129-2132

24) 田中正利: 遺伝子診断法のメリット, デメリット-LCR法による淋菌感染症の診断を中心に. 日本性感染症学会誌 1997; 8: 9-16

25) 渡辺祐子, 黒木俊郎: Infectious Agents Surveillance Report 1998, Vol.19, No.9 (No.223).

26) 1998 Guidelines for treatment of sexually transmitted disease. Centers for Disease Control and Prevention.MMWR 1998;47(RR-1):1-111

P.125 掲載の参考文献

1) 東昇: トラコーマとその病原体. 細菌とウイルスの間(岩波新書). 1969; pp108-178, 岩波書店, 東京

2) 橋爪壮: クラミジア序説. クラミジア感染症の基礎と臨床. 1988; pp1-11, 金原出版, 東京

3) Thygeson P:Trachoma virus:Historical background and review of isolates. NY Acad Sci 1962;98:6-13

4) Page LA:Revision of the family Chlamydiaceae Rake(Rickettsiales):Unification of thepsittacosis-lymphogranuloma venereum-trachoma group of organisms in the genus chlamydia,Jones, Rake and Stearns,1945.Int J Syst Bacteriol 1966;16:223-252

5) Schafter J:Biology of Chlamydia trachomatis. Sexually Transmitted Diseases (Holmes KK, etal, eds),2nd ed.1990;pp 167-180, Mc Graw-Hill, New York

6) 多村憲, 鶴原喬: ライフサイクルと病原性. クラミジア感染症の基礎と臨床. 1988; pp12-31, 金原出版, 東京

7) 萩原敏且: クラミジア感染の基礎及び感染状況. Prog Med 1993; 13: 2400-2406

8) Winkler B, Crum CP:Chlamydia trachomatis infection of the female genital tract. Pathology Annual (Rosen PP, Fechner RE, eds), Part 1/vol 22.1987;pp 193-223, Appleton-Century-Crofts, Connecticut

9) Cates W Jr, Wasserheit JN:Genital chlamydial infection:Epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1767-1781

10) 菅生元康, 南澤豊, 郭宗明, ほか: Enzyme immunoassay法による周産期Chlamydia trachomatis感染症の検索. 日本産科婦人科学会雑誌 1988; 40: 74-80

11) Koroku M, Kumamoto Y, Hirose T, et al:Epidemiologic study of Chlamydia trachomatisinfection in pregnant women. Sex Transm Dis 1994;21:329-331

12) From the CDC:Chlamydia trachomatis genital infections-United States,1995. JAMA 1997;277:952-953

13) Randall T:New tools ready for Chlamydia diagnosis, treatment, but teens needs education most.JAMA 1993;269:2716-2717

14) Herrmann B, Egger M:Genital Chlamydia trachomatis infections in Uppsala County, Sweden,1985-1993:Declining rates for how much longer?Sex Transm Dis 1995;22:253-260

15) 菅生元康, 本藤徹, 滝沢通, ほか: クラミジア感染. 産科と婦人科 1992; 59: 1011-1018

16) 菅生元康, 南澤豊, 郭宗明, ほか: 右上腹部痛をともなったChlamydia trachomatis頸管炎. 日本産科婦人科学会雑誌 1987; 39: 1675-1678

17) 菅生元康: 女子の急性腹症と性感染症. 臨床医 1989; 15: 990-993

18) Rietmeijer CA, Yamaguchi KJ, Ortiz CG, et al:Feasibility and yield of screening urine for Chlamydia trachomatis by polymerase chain reaction among high-risk male youth in field-based and other nonclinic settings.Sex Transm Dis 1997;24:429-435

19) Witkin SS, Inglis SR, Polaneczky M:Detection of Chlamydia trachomatis and Trichomonasvaginalis by polymerase chain reaction in introital specimens from pregnant women. Am J Obstet Gynecol 1996;175:165-167

20) Polaneczky M, Claire Q, Pollock L, et al:use of self-collected vaginal specimens for detectionof Chlamydia trachomatis infection. Obstet Gynecol 1998;91:375-378

21) Johnson RB:The role of azalide antibiotics in the treatment of chlamydia. Am J Obstet Gynecol 1991;164:1794-1796

22) Adair CD, Gunter M, Stovall TG, et al:Chlamydia in pregnancy:A randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998;91:165-1681

23) 笠松高弘, 菅生元康, 吉川裕之, ほか: Chlamydia trachomatis女性性器感染症の診断および治療における血清特異的IgA抗体の意義. 日本産科婦人科学会雑誌 1989; 41: 479-486

P.137 掲載の参考文献

1) 厚生省保健医療局エイズ結核感染症課: 平成10年厚生省感染症サーベイランス事業年報.

2) Wald A:Subclinical shedding of herpes simplex virus in the genital tract:Implications for transmission. Herpes J 1997;4:30-35

3) Nahmias AJ, Roizman B:Infection with herpes simplex viruses 1 and 2.N Engl Med 1973;289:667-674

4) 川名尚, 橋戸円: 性器ヘルペス. 臨床と微生物 1993; 20: 705-712

5) Nahmias AJ, Dannenbarger J, Wickliffle C, et al:Clinical aspects of infection with simplex viruses 1 and 2. The Human Herpesviruses(Nahmias AJ, Dowdle WR, Schinazi R, eds).1981,pp 3-9, Elsevier, Amsterdam

6) Kawana T, Kawaguchi T, Sakamoto S:Clinical and virological studies on genital herpes. Lancet 1976;ii:964

7) Kawana T, Kawagoe K, Takizawa K, et al:Clinical and virologic studies on female genital herpes. Obstet Gynecol 1982;60:456-461

8) 川名尚, 小泉佳男, 土井陽子, ほか: EIAによる単純ヘルペスウイルス抗原検出のためのキット「ヘルプチェック」の評価. 日本性感染症学会誌 1988; 9: 70-72

9) 川名尚: 外陰潰瘍. 産婦人科の実際 1988; 37: 1597-1600

10) Hashido M, Lee FK, Inouye S, et al:Detection of Herpes simplex virus type-specific antibodies by an enzyme-linked immunosorbent assay based on glycoprotein G. J Med Virol 1997;53:319-323

11) 川名尚, 橋戸円: 急性性器ヘルペスに対する経口Acyclovir錠の効果. 感染症学雑誌 1988; 62: 313-321

12) 1988 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and prevention.MMWR PVR 1998;47 (RR-1):1-111

13) Whitley R, Field HJ:Famiciclovir/penciclovir workshop:Introduction. Antiviral Chemotherapy & Chemothery 1993; 4 (suppl 1):1

P.142 掲載の参考文献

1) Almelda JD, Oriel JD, Stannard LM:Characterization of the virus found in human genital warts.Microbios 1969;3:225-232

2) de Villiers E-M, Gissmann L, zur Hausen H:Molecular cloning of viral DNA from human genital warts. J Virol 1981;40:932-935

3) Gissmann L, Diel V, Schultz-Coulon HJ, et al:Molecular cloning and characterization of human papillomavirus DNA derived from a laryngeal papilloma. J Virol 1983;44:393-400

4) Orlel JD:Natural history of genital warts. Br J Vener Dis 1971;47:1-13

5) 吉川裕之: ウイルスの母子感染-パピローマウイルス. 日本新生児学会雑誌 1989; 25: 37-40

6) Yoshikawa H, Matsukura T, Yoshiike K, et al:Human papilloma virus DNA in female condylomata.Acta Obstet Gynaecol Jpn 1985;37:1225-1230

7) Yoshikawa H, Kawana T, Kitagawa K, et al:Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn Cancer Res 1991;82:524-531

8) Nagano H, Yoshikawa H, Kawana T, et al:Association of multiple human papillomavirus types with vulvar neoplasias. J Obstet Gynaecol Res 1996;22:1-8
pubmed

9) Matsumoto K, Yoshikawa H, Taketani Y, et al:Antibodies to human papillomaviruses 16,18,58,and 6b major capsid proteins among Japanese females. Jpn J Cancer Res 1997;88:367-375

P.147 掲載の参考文献

1) 佐々学: ヒゼンダニ. ケジラミ. 人体病害動物学. 1969: p58, p64, 医学書院, 東京

2) 佐分利保雄, 馬場直子, 田中祐志, ほか: 幼児毛風症例とケジラミの微細構造. 日本医事新報 1997: 3825: 27-31

3) Wilson DC. Leyva WH, King LE:Arthropod bites and stings.Dermatology in General Medicine (Fitzpatrick TB, et al, eds), 4th ed.1993;pp2819-2821, McGraw-Hill, New York

P.155 掲載の参考文献

1) Gottlieb MS, Schrofr R, Schanker HM, et al:Pneumocystis carinii pneumonia and mucosal candidias is in previously healthy homosexual men:Evidence of a new acquired cellular immunodeficiency.N Engl J Med 1981;305:1425-1431

2) Barre-Sinoussi F, Chermann C, Rey F, et al:Isolation of a T-lymphotropic retrovirus from apatient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983;220:868-871

3) Clavel F, Guetard D, Brun-Vezinet F, et al:Isolation of a new human retrovirus from west African patient with AIDS. Science 1986;233:343-346

4) CDC:Case control study of HIV seroconversion in health-care workers after percutaneous exposure to V-infected blood-France, United Kingdom, and United States, January 1988-August 1994.MMWR 1995;44:929-933

5) Connor EM, Sperling RS, Gelber R, et al:Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.N Engl J Med 1994;331:1173-1180

6) CDC:Update:Trends in AIDS incidence United States,1996.MMWR 1997;46:861
pubmed

7) Feng Y, Broder CC, Kennedy PE, et al:HIV-1 entry cofactor:Functional CDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877
pubmed

8) Dragic T, Litwin V, Allaway GP, et al:HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673

9) Perelson AS, Neumann AU, Markowitz M, et al:HIV-1 dynamics in vivo:Virion clearance rate,infected cell life-span, and viral generation time. Science 1996;271:1582-1586

10) Mellors JW, Rinaldo CR Jr, Gupta P, et al:Prognosis in HIV-1 infection predicted by the equantity of virus in plasma. Science 1996;272:1167-1170

11) Cooper DA, Gold J, Maclean P, et al:Acute AIDS retrovirus infection:Definition of a clinical illness associated with seroconversion. Lancet 1985;i:537-540

12) Ho DD, Sarngadharan MG, Resnick L, et al:Primary human T-lymphotropic virus type III infection.Ann Intern Med 1985;103:880-883

13) CDC:Classification system for human T-lymphotropic type III/lymphadenopathy-associated virus infection. MMWR 1986;35:334

14) CDC:1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR 1992;41(RR-17):1

15) Hammer SM, Katzenstein DA, Hughes MD, et al:Atrial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-1090

16) Katzenstein DA, Hammer SM, Hughes MD, et al:The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1098

17) Delta Coordinating Committee:Delta:A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996;348:283-291

18) Gulick RM, Mellors JW, Havlir D, et al:Treatment with indinavir, zidovudine, and lamivudinein adults with human immunodeficiency virus infection and prior antiretroviral therapy.N Engl J Med 1997;337:734-739

19) Carpenter CC, Fischl MA, Hammer SM, et al:Antiretroviral therapy for HIV infection in 1996:Recommendations of an international panel. JAMA 1996;276:146-154

20) Carpenter CC, Fischl MA, Hammer SM, et al:Antiretroviral therapy for HIV infection in 1997:Updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-1969

21) Burgard M, Mayaux MJ, Blanche S, et al:The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. N Engl J Med 1992;327:1192-1197

22) European Collaborative Study:Risk factors for mother-to-child transmission of HIV-1.Lancet 1992;339:1007
pubmed

23) Wade NA, Birkhead GS, Warren BL, et al:Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-1414

24) Seeff LB and Veterans Administration Cooperative Study Group:Type B hepatitis after needle stick exposure:Prevention with hepatitis B immune globulin. Ann Intern Med 1978;88:285-293

25) Grady GF, Lee VA, Prince AM, et al:Hepatitis B immune globulin for accidental exposures among medical personnel:Final report of a multicenter controlled trial. J Infect Dis 1978;138:625-638

26) Kaufmann M, Bode JC:Risk ofhepatitis C virus infection in medical occupations. Versicherungs medizin 1997;491132-134

27) CDC:Occupationally acquired cases by occupation. HIV/AIDS Survellance Report 1997;9:11

28) Tokars JI, Marcus R, Culver DH, et al:Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913-
pubmed

29) CDC:Update:Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-480

P.160 掲載の参考文献

1) Lossick JG, Kent HL:Trichomoniiasis:Trends in diagnosis and management. Am J Obstet Gynecol 1991;165:1217-1222

2) Sobel JD:Vaginitis.V Engl J Med 1997;337:1896-1903

P.165 掲載の参考文献

1) 石川睦男: 産婦人科領域の感染症. 新抗菌薬の使い方, 第4版, 1998; pp187-202, 三共, 東京

2) 高田道夫: 真菌感染-産婦人科領域真菌症の疫学. 図説臨床産婦人科講座21, 産婦人科と感染症. 1979; pp142-155, メジカルビュー社, 東京

3) 高田道夫: Candida症. 性と感染(STD)-性感染症学. 1990; pp280-290, 医薬ジャーナル社, 大阪

4) 木村好秀: 外陰の感染症チェックポイント-真菌感染症. 産婦人科の実際 1997; 46: 661-667

5) 高田道夫: 真菌症の診断と治療. 産婦人科治療 1986; 52: 681-684

6) 木村好秀: 真菌感染と検査. 周産期医学 1993; 23: 240-246

7) 深沢一雄, 稲葉憲之: 特異性感染症-カンジダ. 図説産婦人科 VIEW 5, 性感染症. 1994; pp133-135, メジカルビュー社, 東京

8) 清水哲也, 千石一雄: 膣炎とその治療. 産婦人科治療 1990; 61: 592-594

9) 滝沢憲: 外陰・腔カンジダ症とその治療法. 産婦人科治療 1997; 74: 400-404

10) 水野重光: 外陰膣カンジダ症に対するオキナゾール膣錠の二重盲検臨床試験- 一日療法. 産婦人科の世界 1989; 41: 633-640

11) 鈴木正明: 難治性膣真菌症. 臨床婦人科産科 1993; 47: 1116-1117

12) 久保田武美: 難治性感染症-反復性膣炎. 臨床婦人科産科 1994; 48: 1260-1261

13) Spinillo A:Recurrent vaginal candidiasis.,Reprod Med 1992;37:343-347

14) Sobel JD:Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992;14 (suppl 1):S 148-S 153

15) 伊藤章: 抗真菌剤をめぐる話題. 産婦人科治療 1997; 74: 391-393

16) Roge rs TE, Galgiani JN:Activity of fluconazole and ketoconazole against Candida albicans in vitro and in vivo.Antimicrob Agents Chemother 1986;30:418-422

17) Rex JH, Bennett JE, Sugar AM, et al:A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Engl J Med 1994;331:1325-1330

P.181 掲載の参考文献

1) 西岡久壽彌: 血液由来ウイルスと性感染. 日本性感染症学雑誌 1990; 1: 7-13

2) CDC: Summary of Notifiable Disease United States 1995. MMWR 1996; 44(53): 3

3) 厚生省統計情報部: 平成7年伝染病統計. 1996; 厚生統計協会, 東京

4) 厚生省: 感染症サーベイランス事業年報平成5年. 1996

5) 東京都: 感染症サーベイランス事業報告書(平成7年). 1996

6) 芦沢正見: 性病予防法の問題点とその因由. 公衆衛生院研究報告 1990; 39: 145-147

7) 小島弘敬: エイズキャンペーンの男子尿道炎症例数に及ぼした影響. 日本公衆衛生雑誌 1996; 43: 545-550

8) Ohbayashi A, Okochi K, Mayumi M, et al:Familial clustering of asymptomatic carriers of Australia antigen and patients with chronic liver disease or primary liver cancer.Gastroenterology 1972;62:618-625

9) 栗村統, 浜田金三郎, 香川治子: 配偶者間におけるHB抗原の感染. 肝臓 1975; 16: 36-39

10) 大林明, 吉川雄二, 八森啓, ほか: 最近の急性B型肝炎の感染様式とその頻度. 日本医事新報 1984; 3137: 28-31

11) 森山光彦, 片庭義雄, 竹内正, ほか: 東京地区の売春婦人における肝炎ウイルスの感染について. 肝臓 1984; 25: 985-989

12) 中尾昌弘, 門名丈之: 我が国におけるB型肝炎の疫学動向. 日本臨牀 1995; 53(増刊号): 331-336

13) 中島孝哉, 柏木征三郎, 林純, ほか: 特殊浴場従業員におけるHBV, HTLV-1, HIV感染の経時的検討. 日本性感染症学雑誌 1992; 3: 17-22

14) Alexander NJ:Sexual transmission of human immunodeficiency virus. Fertil Steril 1990;54:1-18

15) Plummer FA, Simonsen JN, Cameron DW, et al:Cofactors in male-female sexual transmission of human immunodeficiency virus type 1.Infect Dis 1991;163:233-239

16) Grosskurth H, Mosha F, Todd J, et al:Impact of improved treatment of STDs on HIV infectionin rural Tanzania:Randomised controlled trial. Lancet 1995;346:530-536

17) 小島弘敬, 高井計弘: 日本と欧米諸国とのHIV流行像の相違. 日本性感染症学雑誌 1994; 5: 134-137

18) 木原正博(編): Current Situation of HIV/AIDS Epidemic. 第8回エイズの疫学と対策ワークショップ記録. 1998; pp1-32

19) Okochi K, Sato H, Hinuma Y:A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion:Seroconversion in recipients. Vox Sang 1983;46:245-249

20) Kaj iyama W, Kashiwagi S, Ikematsu H, et al:Intrafamilial transmission of adult T-cell leukemia virus. J Inflect Dis 1986;154:851-857

21) 三井幸彦: トラコーマ. 日本眼科全書(日本眼科学会, 編), 第16巻. 1955, 金原出版, 東京

22) Grimes DA:Family planning and STD. STD(Holmes KK, et al, eds).1990;pp 1087-1094,Mc Graw-Hill, New York

23) 北村邦夫: ピルの認可は性感染症を蔓延させるか. 治療学 1997; 31: 869-872

24) 熊本悦明, 佐藤隆志, 広瀬崇興, ほか: 尿路性器 Chlamydia trachomatis感染症の疫学調査. 日本性感染症学雑誌 1994; 5: 32-42

25) 小松淳子, 折津政江, 小島弘敬, ほか: 健康診断受診者におけるChlamydia trachomatis抗体の検討. 日本総合健診医学会誌 1990; 17: 302-306

26) Kojima H, Wang SP, Grayston JT, et al:Local antibody in semen for rapid diagnosis of Chlamydia trachomatis epididymitis.Urol 1988;140:528-531

27) Sugase M, Moriyama S, Matsukura T, et al:Human papillomavirus in exophytic condylomatous lesions on different female genital regions. J Med Virol 1991;34:1-6
pubmed

28) 菅生元康, 己斐澄子, 羽田悟, ほか: 女性性器におけるヒト・パピローマウイルス感染症. 産婦人科治療 1987; 54: 12-18

29) Wang SP, Grayston JT:Human serology in C. trachomatis infections with microimmuno-fluorescence. Infect Dis 1974;130:388-397

30) Piura B, Sarov B, Kleinman D, et al:Serum Igg and Iga antibodies specific for Chlamydiatrachomatis in salpingitis patients as determined by immunoperoxidase assay. Eur J Epidemiol 1985;1:110-116

31) 小島弘敬, 木谷孔保, 矢野惣一, ほか: クラミジア抗体検出についての一点希釈EIA法と倍数希釈法との比較. 医学と薬学 1994; 32: 1029-1035

32) 小島弘敬, 高井計弘, 深澤立: クラミジア尿道炎, 頸管炎症例の初診時におけるクラミジアIgM抗体検出の意義. 日本性感染症学雑誌 1996; 7: 43-47

33) 小島弘敬, 高井計弘, 野口泰子, ほか: Chlamydia trachomatis尿道炎, 頸管炎症例の初診時における罹患部スワブEIA反応値と血清抗体価の分布. 臨床病理 1996; 44: 153-158

34) 橋戸円, 川名尚: 単純ヘルペスウイルスの検査(基礎). 日本性感染症学雑誌 1991; 2: 50-57

35) 本田まり子, 新村眞人: 性器ヘルペスの検査法の適用の仕方とその読み方. 日本性感染症学雑誌 1991; 2: 58-62

36) 野口昌良, 岡本俊充, 秋田敏行, ほか: 産婦人科におけるChlamydia trachomatis感染症に関する臨床的検討. 日本産科婦人科学会雑誌 1988; 40: 452-458

37) 野口昌良: Chlamydia trachomatis感染症の現状と問題点. クラミジア・ニューモニエ感染症の現状と問題点(千葉峻三, 沼崎啓, 編). 1997; pp167-176, ライフサイエンス・メディカ, 東京

38) Scholes D, Stergachis A, Heidrich FE, et al:Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-1366

39) Oriel JD, Ridgway GL(eds):Genital Infection by Chlamydia trachomatis.1982, Edward Arnold, London

40) Schachter J:Chlamydial infection. N Engl J Med 1978;298:428-435

41) 小島弘敬, 森田豊寿, 野口泰子, ほか: 淋菌, クラミジアの非培養検出法反応値による感染局所菌量の推定. 日本性感染症学会誌 1993; 4: 83-87

42) 小島弘敬, 高井計弘: クラミジア尿道炎患者の尿道各部位からのスワブ採取によるクラミジア抗原の尿道内分布. 日本性感染症学会誌 1995; 6: 13-16

43) 小島弘敬: Chlamydia trachomatis(CT)頸管炎患者の頸管周辺部のCT抗原分布. 日本産科婦人科学会雑誌 1996; 48: 343-346

44) Caldwell JG, Price EV, Pagin GJ, et al:Sensitivity and reproducibility of Thayer-Martin culture medium in diagnosing gonorrhea in women.Am J Obstet Gynecol 1971;109:463-468

45) 常松之典, 亀井喜世子, 水間圭祐, ほか: 街娼の淋菌感染診断についてのLC培地の評価. 日本細菌学雑誌 1977; 32: 363-368

46) 小島弘敬, 森忠三, 高井計弘, ほか: 淋菌, クラミジア検出における各種検出法の偽陽性反応. 日本性感染症学会誌 1990; 1: 61-65

47) 高野俊之, 浜中輝彦, 石田敬子, ほか: 蛍光抗体法, 酵素抗体法で検出された新生児クラミジア結膜炎の14症例. 眼科臨床医報 1988; 82: 1942-1949

48) Tice AW, Rodriguez VL:Pharyngeal gonorrhea. JAMA 1981; 246 2717-2719

49) Dans PE:Gonococcal anogenital infection. Clin Obstet Gynecol 1975;18:103-107

50) 津上久彌, 丸山治朗: Oral sexとSTD. 性と感染(STD)-性感染症学(熊本悦明, 島田馨, 川名尚, 編). 1990; pp386-391, 医薬ジャーナル社, 大阪

51) 小島弘敬, 小倉修二, 森田豊寿, ほか: 3症例の淋菌性咽頭炎. 感染症学雑誌 1988; 62: 381-387

52) 小島弘敬, 高井計弘: 淋菌またはクラミジアによる尿道炎および頸管炎患者の咽頭, 直腸における淋菌, クラミジア陽性率. 感染症学雑誌 1994; 68: 1237-1241

53) 高井計弘, 小島弘敬, 河邊香月, ほか: 本邦淋菌臨床分離株の栄養要求型, 血清型と薬剤感受性. 日本泌尿器科学会雑誌 1995; 86: 325-332

54) 岡崎武二郎, 町田豊平, 小野寺昭一, ほか: ニューキノロン剤耐性淋菌の検出. 日本性感染症学雑誌 1993; 4: 88-91

55) 小島弘敬: 薬剤耐性淋菌による感染症. 産婦人科の実際 1992; 41: 1085-1094

56) 斉藤功: One shot療法について. STD-病因・診断・治療. 臨床と細菌(臨時増刊号) 1984; 11: 37-43

57) Miyashita N, Iijima Y, Matsumoto A:Evaluation of the sensitivity and specificity of PCR testkit, AMPLICOR Chlamydia trachomatis.Microbiol Immunol 1994;38:81-85

58) 小島弘敬: 尿沈渣を検体としてのPCRによるChlamydia trachomatis診断キットのとくに女子 C. trachomatis生殖器感染症についての有用性. 感染症学雑誌 1997; 71: 709-714

59) 小島弘敬, 森忠三: Chlamydia trachomatis生殖器感染症のMinocycline内服による治療成績. 感染症学雑誌 1985; 59: 824-830

60) 小島弘敬, 森忠三: Chlamydia trachomatis尿道炎のDoxycyclineによる治療. Jpn J Antibiot 1985; 38: 3179-3187

61) 岡崎武二郎, 高畠浩, 角ゆかり, ほか: クラミジア陽性妊婦の配偶者におけるクラミジア感染状況. 感染症学雑誌 1993; 67: 1-6

P.191 掲載の参考文献

1) Amsel R, Totten PA, Spiegel CA, et al:Nonspecific vaginitis:Diagnostic criteria and microbialand epidemiologic association. Am J Med 1983;74:14-22

2) Eshenbach DA:History and review ofbacterial vaginosis. Am J Obstet Gynecol 1993;169:441-445

3) Gibbs RS:Chorioamnionitis and bacterial vaginosis. Am J Obstet Gynecol 1993;169:460-462

4) Mc Gregor JA, French JI, Seo K:Premature rupture of membranes and bacterial vaginosis. Am J Obstet Gynecol 1993;169:463-466

5) Soper DE:Bacterial vaginosis and postoperative infection. Am J Obstet Gynecol 1993;169:467-469

6) Faro S, Martens M, Maccato M, et al:Vaginal fiora and pelvic inflammatory disease. Am J Obstet Gynecol 1993;169:470-473

7) Kubota T, Utsuno S, Takeuchi H, et al:Detection and identification of amines in bacterial vaginosis.J Obstet Gynaecol 1995;21:51-55

8) 久保田武美: 外陰・膣真菌症と腔トリコモナス症. 産婦人科の実際 1984; 33: 559-567

9) 久保田武美: 反復性膣炎. 臨床婦人科産科 1994; 48: 1260-1261

10) 久保田武美: 細菌性膣症におけるアミン呈色反応の検討. 産科と婦人科 1995; 62: 107-111

11) Nugent RP, Krohn MA, Hiller SL:Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297-301

12) 松田静治: 外陰膣の感染症. 産婦人科領域感染症. 1988; pp51-63, 医薬ジャーナル社, 大阪

P.195 掲載の参考文献

1) 宮地徹, 森脇昭介, 櫻井幹己: 産婦人科病理学診断図譜. 1987; pp82-84, 杏林書院, 東京

2) Wright TC, Ferenczy A:Benign disease of the cervix. Blaustein's Pathology of the Female Genital Tract(Kurman RJ, ed),4th ed.1994;pp 203-227, Springer-Verlag, New York

3) 日本産科婦人科学会(編): 産科婦人科用語集. 1995, 金原出版, 東京

4) Holmes KK:Lower genital tract infections in women:Cystitis/urethritis, vulvovaginitis and cervicitis. Sexually Transmitted Diseases(Holmes KK, Mardh PA, Sparling PF, et al, eds).1990;pp557-589, McGraw-Hill, New York

5) Schaefer G:Tuberculosis of female genital tract. Clin Obstet Gynecol 1970;13:965-998

6) Hoosen AA, Draper G, Cooper K:Granuloma inguinale of the cervix:A carcinoma look-alike.Genitourin Med 1990;66:380-382

7) Pereira LH, Embil JA, Haase DA, et al:Cytomegalovirus infection among women attending a sexually transmitted disease clinic:Association with clinical symptoms and other sexually transmitted diseases. Am J Epidemiol 1990;131:683-692

8) Schwartz DA:Carcinoma of the uterine cervix and schistosomiasis in West Africa. Gynecol Oncol 1984;19:365-370

9) Wilbanks GD, Carter B:Vaginitis emphysematosa. Obstet Gynecol 1963;22:301-309

10) Gardner HL, Fernet P:Etiology of vaginitis emphysematosa. Am J Obstet Gynecol 1964;88:680-694

11) Newton WL, Reardon LV, Deleva AM:A comparative study of the subcutaneous inoculation of germ-free and conventional guinea pigs with two strains of Trichomonas vaginalis. Am J Trop Med Hyg 1960;9:56-61

P.201 掲載の参考文献

1) Casey BM, Cox SM:Chorioamnionitis and endometritis. Infect Dis Clin North Am 1997;11:203-222

2) 岡田弘二, 松田静治: 子宮体内膜炎. 産婦人科領域感染症. 1988; pp69-72, 医薬ジャーナル社, 大阪

3) Jones R, Mammel J, Shepard M, et al:Recovery of Chlamydia trachomatis from the endometrium Of women at risk for Chlamydial infection. Am J Obstet Gynecol 1986;155:35-39

4) Stray-Pedersen B, Bruu A-L, Molne K:Infertility and uterine colonization with Ureaplasmaurealyticum. Acta Obstet Gynecol Scand 1982;61:224

5) Taylor-Robinson D, Mc Cormac WM:The genital mycoplasmas. N Engl J Med 1980;302:1003-1010

6) Gonpel C, Silverberg SG:Inflammatory disease of the endometrium. Pathology in Gynecology and Obstetrics,4th ed.1994;pp 211-216, JB Lippincott, Philadelphia

7) 滝沢憲: 産科(周産期)におけるMRSA感染症と対策. 産婦人科の実際 1995; 44: 1915-1919

8) Kiviat NB, Wolner-Hanssen P, Eschenbach DA, et al:Endometrial histopathology in patients with culture proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am J Surg Pathol 1990;14:167-175

9) Crum CP, Egawa K, Fenoglio CM, et al:Chronic endometritis:The role of immunohistochemistry in the detection of plasma cells. Am J Obstet Gynecol 1983;147:812-815

10) 加藤俊, 薬師寺道明: 子宮の炎症. 現代産科婦人科学大系8A, 女性性器の奇形発育・位置異常損傷炎症. 1971; pp247-258, 中山書店, 東京

P.209 掲載の参考文献

1) Sweet RL, Gibbs RS:Pelvic inflammatory diseases. Infectious Diseases of the Female Genital Tract, 3rd ed. 1995; pp 379-428, Williams & Wilkins, Baltimore

2) 保田仁介: PIDとはどのような疾患か. 産婦人科感染症Q&A(松田静治, 編). 1998; PP54-61, 医薬ジャーナル社, 大阪

3) Wolner-Hanssen P, Kiviat NB, Holmes KK:Atypical pelvic inflammatory disease:Subacute, chronic, or subclinical upper genital tract infection in women. Sexually Transmitted Diseases (Holmes KK, Mardh P, Sparling PF, et al, eds). 1990; pp615-620, McGraw-Hill, New York

4) 日本産科婦人科学会(編): 産婦人科用語集, 第4版. 1995, 金原出版, 東京

5) 日本産科婦人科学会(編): 産婦人科用語解説集, 第2版. 1997, 金原出版, 東京

6) Eschenbach DA, Bachanan T, Pollock T, et al:Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 1975; 293:166

7) 玉舎輝彦: 嫌気性菌感染症をめぐって-産婦人科領域. 臨床と微生物 1998; 25: 573-579

8) Sweet RL, Gibbs RS:Chlamydial infection. Infectious Diseases of the Female Genital Tract, 3rd ed. 1995; pp 64-110, Williams & Wilkins, Baltimore

9) 保田仁介: 産婦人科. 最新・感染症治療指針(島田馨, 編). 1998; pp172-179, 医薬ジャーナル社, 大阪

10) Eschenbach DA, Harnisch JP, Holmes KK:Pathogenesis of acute pelvic inflammatory disease:Role of contraception and other risk factors. Am J Obstet Gynecol 1977; 128:838
pubmed

11) Westrom L:Incidence, prevalence and trends of acute pelvic inflammatory disease and its cosequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880

12) Sweet RL:Pelvic inflammatory disease and infertility in women. Infect Dis Clin North Am 1987;1:199-215

13) Washington AE, Cates W, Zadi AA:Hospitalization for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975 to 1981. JAMA 1984;251:2529-2533

14) Roffs RT, Galaid E, Zaidii AA:Epidemiology of pelvic inflammatory disease:Trends in hospitalization and office visit, 1979-1988. Joint Meeting of the Center for Disease Control and National Institute of Health about Pelvic Inflammatory Disease Prevention, Management and Research in the 1990s. September 4-5, 1990; Bethesda, Maryland

15) 岡田弘二, 保田仁介: 産婦人科領域感染症の現況と対策. 日本医師会雑誌 1993; 110: 137-140

16) 保田仁介: クラミジア・トラコマチス感染症の診断. 産科と婦人科 1997; 64: 441-446

17) 保田仁介, 岩破一博, 藤原葉一郎, ほか: クラミジア抗原検出陰性PIDの臨床的取り扱いについての検討. 日本性感染症学会誌 1991; 2: 89-93

18) 保田仁介: クラミジア核酸同定. 綜合臨牀(検査データマニュアル) 1998; 47: 1700-1701

19) 保田仁介: クラミジア抗体, 抗原. 綜合臨牀(検査データマニュアル) 1998; 47: 1702-1704

20) 本庄英雄, 保田仁介: 感染症治療薬と副作用対策. 妊産婦の感染症治療の手びき(松田静治, 編). 1998; pp32-39, ヴァンメディカル, 東京

P.215 掲載の参考文献

1) 泉孝英: わが国における結核の現状と将来-今後の結核対策. 結核. 1998; pp417-420, 医学書院, 東京

2) 森亨: 結核. 綜合臨牀 1997; 46: 1550-1554

3) Moore M, Onorato IM, Mc Cray E, et al:Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278:833-837

4) 国立大学保健管理施設協議会エイズ特別委員会: エイズ-教職員のためのガイドブック'98.

5) 矢野郁也: 結核菌の性状. 結核. 1998; pp9-11, 医学書院, 東京

6) 日本結核病学会教育委員会: 結核症の基礎知識. Kekkaku 1997; 72: 523-545

7) 鈴木克洋: 結核菌検査. 結核. 1998; pp107-113, 医学書院, 東京

8) Anderson JR:Genital tuberculosis. Novak's Textbook of Gynecology (Jones HW, et al, eds), 1988; pp 557-569, Williams & Wilkins, Baltimore

9) 水野金一郎: 女性性器結核. 結核. 1998; pp250-252, 医学書院, 東京

10) 高橋睦夫, 平岡芙美子, 伊世悦子, ほか: 子宮体部明細胞腺癌に結核症を合併した1例. 日本臨床細胞学会雑誌 1993; 32: 447-452

11) 伊東武久, 矢壁昭人, 高崎彰久, ほか: 当院10年間のMicrosurgeryの成績. 産婦人科マイクロサージャリー学会雑誌 1988; 1: 11-13

12) 河上征治: 卵管形成術. 産婦人科の世界 1979; 31: 567-574

13) 佐藤育男, 竹内理恵, 野末悦子, ほか: 細胞診で結核性子宮内膜炎を疑った5症例. 日本臨床細胞学会雑誌 1992; 31: 65-69

14) 桜井幹己: 内膜の炎症性疾患. 産婦人科病理学診断図譜. 1987; pp181-182, 杏林書院, 東京

15) 川城丈夫: 肺結核. 日本医師会雑誌 1996; 116(臨増): 137-139

P.221 掲載の参考文献

1) 野口昌良, 岡本俊充, 稗田茂雄, ほか: 卵管性不妊症とChlamydia trachomatis感染に関する検討. 日本不妊学会雑誌 1990; 35: 547-551

2) 笠松高弘, 菅生元康, 吉川裕之, ほか: Chlamydia trachomatis女性性器感染症の診断および治療における血清特異的IgA抗体の意義. 日本産科婦人科学会雑誌 1989; 41: 479-486

3) 野口昌良, 岡本俊充, 保条説彦, ほか: 卵管性不妊患者におけるクラミジア・トラコマテス抗体の検討-セロ・イパライザークラミジアIgA, IgG, IgMを用いて. 日本不妊学会雑誌 1997; 42: 787-791

4) Anestad G, Lunde O, Moen M, et al:Infertility and chlamydial infection. Fertil Steril 1987; 48:787-791

5) 白石尚美, 長田尚夫, 白川貴士, ほか: 不妊患者におけるクラミジア抗原, 抗体の測定意義について. 産婦人科マイクロサージャリー学会雑誌 1995; 8: 18-20

P.228 掲載の参考文献

1) 熊本悦明, 塚本泰司, 広瀬崇興, ほか: 尿路感染症分離菌に対する経口並びに注射用抗菌薬の抗菌力比較(第18報1996年). Jpn J Antibiot 1998; 51: 69-236

2) Fowler JE Jr:Urinary tract infection in women. Urol Clin North Am 1986; 13:673-683

3) 田仲紀明, 熊本悦明, 岡山悟, ほか: 急性腎盂腎炎における尿中β2-microglobulin, N-acetyl-β-D-glucosaminidase(NAG)の診断的意義の検討. 日本泌尿器科学会雑誌 1987; 78: 649-660

4) Molander U, Milsom I, Ekelund P, et al:Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post menopause. Maturitas 1990;12:113-120

5) Schaeffer AJ, Amundsen SK, Schmidt LN:Adherence of Escherichia coli to human urinary tractepithelial cells. Infect Immun 1979;24:753-759

6) Craig WA:The postantibiotic effect. Antibiotis in Laboratory Medicine (Lorian V, ed), 2nd ed.19 86; pp 515-536, William s & Wilkins, Baltimore

7) 広瀬崇興, 西村昌宏: 1回投与(単回療法). 泌尿器科MOOK 1, 尿路・性器感染症(熊澤淨一, 編). 1992; pp70-78, 金原出版, 東京

8) Kumon H:Pathogenesis and management of bacterial biofilms in the urinary tract. J Infect Chemother 1996; 2:18-28

9) 横尾彰文, 熊本悦明, 広瀬崇興: 尿路感染症の難治化, 再発化に関与する背景因子の分析-多変量解析による重回帰分析での検討. 感染症学雑誌 1994; 68: 905-915

10) Kunin CM:Management of urinary tract infection. Urinary Tract Infections:Detection, Preventon, and Management (Kunin CM, ed),5th ed. 1997; pp 363-396, Willams & Wilkins, Baltimore

11) Raz R, Stamm WE:A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753-756

12)Smith PJB:The management of the urethral syndrome. Br J Hosp Med 1979; 22:578-587

13) Kaplan WE, Firlit CF, Schoenberg HW:The female urethral syndrome:External sphincter spasm as etiology. J Urol 1980;124:48-49

14) Sand PK, Bowen LW, Ostergard DR, et al:Cryosurgery versus dilatation and massage for the treatment of recurrent urethral syndrome. J Reprod Med 1989; 34:499-504

P.235 掲載の参考文献

1) Kundsin RB, Driscoll SG:Strain of Mycoplasma associated with human reproductive failure. Science 1967;157:1573-1574

2) Sompolinsky D, Solomon F, Elkina L, et al:Infections with lycoplasma and bacteria in induced midtrimester and fetal loss. Am J Obstet Gynecol 1975; 121:610-616

3) Quinn PA, shewchuk AB, shuber J, et al:Efhcacy of antibiotics therapy in preventing spontaneous pregnancy loss among couples colonized with genital mycoplasmas. Am J Obstet Gynecol 1983;145:239-244

4) Sharf M, Eibschitz I, Eylan E:Latent toxoplasmosis and pregnancy. Obstet Gynecol 1973; 42:349-354

5) Kimball AC, Kean BH, Fuchs F:The role of toxoplasmosis in abortion. Am J Obstet Gnecol 1971; 111:219-226

6) Halliday HL, Hirata T:Perinat Isteriosis:A review of twelve patients. Am J Obstet Gynecol 1979;133:405-410

7) Rapaport F, Rabinovitz M:Genital listeriosis as a cause of repeated abortion. Lancet 1960;i:1273-1275

8) Rabau E, David A:Listeria monocytogenes in abortion. J Obstet Gynecol 1963;70:481-482

9) Martin DH, Koutsky L, Eschenbach DA, et al:Prematurity and perinatal mortality in pregnancies complicated by maternal Chlamydia trachomatis infections. JAMA 1982;247:1585-1588

10) Sweet RL, Landers DV, Walker C, et al:Chlamydia trachomatis infection and pregnancy outcome. Am J Obstet Gynecol 1987;156:824-833

11) Becroft DMO, Farmer K, Mason GH, et al:Perinatal infections by group B beta-hemolytic streptococci. Br J Obstet Gynaecol 1976; 83:960-966

12) Desa DJ, Trevenen CL:Intrauterine infections with group B beta-haemolytic streptococci., Br J Obstet Gynaecol 1984;91:237-239

13) Romero R, Avila C, Brekus CA, et al:The role of systemic and intrauterine infection in preterm parturition. Ann NY Acad Sci 1991; 622:355-375

14) 佐川正: 早産の予知における細菌感染の意義ならびに新しい破水診断試薬の開発について(佐川正, 編). 1994; pp1-40, 響文社, 札幌

15) 佐川正, ベーガムサイエダ, 松田直, ほか: 子宮内感染と羊水情報. ペリネイタルケア 1996; 15: 491-496

16) Guzick DS, Winn K:The association of chorioamnionitis with preterm delivery. Obstet Gynecol 1985; 65:11-16

17) Lettieri L, Vintzileos AM, Rodis JF, et al:Does“idiopathic”preterm labor resulting in pretermbirth exist?Am/ Obstet Gynecol 1993; 168:1480-1485

18) Gravett MG, Hummel D, Eschenbach DA, et al:Preterm labor associated with subclinical amniotic fluid infection and with bacterial vaginosis. Obstet Gynecol 1986;67:229-236

19)odds WG, Iams JD:Maternal C-reactive protein and preterm labor. Reprod Med 1987;32:527-530

20) Minkoff H, Grunebaum AN, Schwarz RH, et al:Risk factors for prematurity and premature rupture of membranes:A prospective study of the vaginal flora in pregnancy Am J Obstet Gynecol 1984;150:965-972

21) Edwards LE, Barrada MI, Hamann AA, et al:Gonorrhea in pregnancy. Am J Obstet Gynecol 1978;132:637-641

22) Amsel R, Totten PA, Spiegel CA, et al:Nonspecific vaginitis:Diagnostic criteria and microbial and epidemiological associations. Am Med 1983;74:14-22

23) Spiegel CA, Amsel R, Holmes KK:Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. Clin Microbiol 1983; 18:170-177

24) Sagawa T, Negishi H, Kishida T, et al:Vaginal and cervical pH in bacterial vaginosis and cervicitis during Pregnancy. Hokkaido J Med Sci 1995;70:839-846

25) Kurki T, Sivonen A, Renkonen OV, et al:Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992;80:173-177

26) Gravett MG, Nelson P, Derouen T, et al:Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 1986; 256:1899-1903

27) Brunham RC, Paavonen J, Stevens CE, et al:Mucopurulent cervicitis:The ignored counterpart in women of urethritis in men. N Engl Med 1984;311:1-6

28) 佐川正, 岸田達朗, 香城恒麿, ほか: 前方視的観察による妊娠時の頸管炎と頸管粘液顆粒球エラスターゼ量との関連. 産婦人科の世界 1994; 46: 295-300

29) Hardt NS, Kostenbauder M, Ogburn M, et al:Influence of chorioamnionitis on long-term prognosis in low birth weight infants. Obstet Gynecol 1985;65:5-10

30) Romero R, Quintero R, Nores J, et al:Amniotic fluid white blood cell count:A rapid and simpletest to diagnose microbial invasion of the amniotic cavity and predict preterm delivery. Am J Obstet Gynecol 1991;165:821-830

31) Romero R, Jimenez C, Lohda AK, et al:Amniotic fluid glucose concentration:A rapid and simple method for the detection of intraamniotic infection in preterm labor. Am J Obstet Gynecol 1990;163:968-974

32) Kirshon B, Rosenfeld B, Mari G, et al:Amniotic fluid glucose and intraamniotic infection. Am J Obstet Gynecol 1991;164:818-820

33) Gauthier DW, Meyer WJ:Comparison of gram stain, leukocyte esterase activity, and amnioticfluid glucose concentration in predicting amniotic fluid culture results in preterm rupture ofmembranes. Am J Obstet(]ynecol 1992;167:1092-1095

34) 平野秀人, 津田晃, 内海透, ほか: 羊水中顆粒球エラスターゼ測定による絨毛羊膜炎の診断と胎児感染の予知の可能性について. 産婦人科の実際 1994; 43: 187-193

35) Hoskins IA, Katz J, Ordorica SA, et al:Esterase activity in second-and third-trimester amnioticfluid:An indicator of chorioamnionitis. Am J Obstet Gynecol 1989;161:1543-1545

36) Puchner T, Egarter C, Wimmer C, et al:Amniotic fluid interleukin-8 as a marker for intra-amniotic infection. Arch Gynecol Obstet 1993;253:9-14

37) 佐川正, 古田伊都子, 藤本征一郎: 早産治療のストラテジー -preterm PROMの予防は可能か. 臨床婦人科産科 1998; 52: 668-673

38) 佐川正: 前期破水(PROM)の取り扱い-教室におけるpreterm PROMの診断・管理とその予防について. 日本産科婦人科学会雑誌 1998; 50: N283-N286

P.246 掲載の参考文献

1) Blanc WA:Amniotic infection syndrome, practical significance and quick diagnostic test. NY State J Med Proceedings 1961;May 1:1488-1492

2) Blanc WA:Amniotic infection syndrome:Pathogenesis, morphology, and significance in circumnatal mortality. Clin Obstet Gynecol 1959;2:705-709

3) Kanayama N, Terao T, Horiuchi K, et al:Collagen types in normal and prematurely ruptured amniotic membranes. Am Obstet Gynecol 1985;153:899-903

4) Kanayama N, Terao T, Horiuchi K, et al:The relationship between trypsin activity in amnioticand premature rupture of membranes. Am Obstet Gynecol 1986;155:1043-1058

5) 寺尾俊彦: 分娩発来機序と免疫. 周産期医学 1994; 24: 1215-1220

6) 寺尾俊彦: 早産の予防. 日本産科婦人科学会雑誌 1996; 48: 660-665

7) Maradny E, Kanayama N, Terao T, et al:Urinary trypsin inhibitor has a protective effect on the amnion. Gynecol Obstet Invest 1994;38:169-172

8) 寺尾俊彦: 周産期をめぐるサイトカイン. 日本産科婦人科学会雑誌 1996; 48: 742-750

9) 寺尾俊彦: PROMとchorioamnionitisの診断法. 日本産科婦人科学会雑誌 1996; 48(3): N47-N50

10) Maradny E, Kanayama N, Terao T, et al:Interleukin-8 induces cervical ripening in rabbits. Am Obstet Gynecol 1994;171:77-83

11) Maradny E, Kanayama N, Terao T, et al:Effects of neutrophil chemotactic factors on cervical ripening. Clin Exp Obstet Gynecol 1995;22:76-85

12) Lockwood CJ, Senyei AE, Dische MR, et al:Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325:669-674

13) Kanayama N, Terao T:The relationship between granulocyte elastase-like activity of cervical mucus and cervical maturation. Acta Obstet Gynecol Scand 1991;70:29-34

14) Limvarapuss C, Kanayama N, Terao T:Elastase activity of endocervical mucus in normal pregnancy. Asia-Oceania J Obstet Gynecol 1992;18:147-153

P.257 掲載の参考文献

1) Gibbs RS:Microbiology of the female genital tract. Am J Obstet Gynecol 1987;156:491-495

2) Ismail MA, Chandler AE, Beem ME:Chlamydial colonization of the cervix in pregnant adolescents. J Reprod Med 1985;30:549-553

3) Cunningham FG, Hauth JC, Strong JD, et al:Infectious morbidity following cesarean:Comparison of two treatment regimens. Obstet Gynecol 1978;52:656-661

4) Dizerega G, Yonekura L, Roy S, et al:A comparison of clindamycin-gentamicin and penicillin-gentamicin in the treatment of post-cesarean section endomyometritis. Am J Obstet Gynecol 1979;134:238-242

5) Cunningham FG, MacDonald PC, Gant NF, et al:Infection and disorders of the puerperium. Williams Obstetrics (Cunningham FG, et al, eds), 20th ed.1997;p553, Appleton & Lange, Stamford

6) Owen J, Andrews WW:Wound complications after cesarean section. Clin Obstet Gynecol 1994;37:842-855

7) Ramin SM, Gilstrap LC:Episiotomy and early repair of dehiscence. Clin Obstet Gynecol 1994;37:816-823

8) Cook JD, Lynch SR:The liabilities of iron deficiency. Blood 1986;68:803-809

9) Suonio S, Huttunen M:Puerperal endometritis after abdominal twin delivery. Acta Obstet Gynecol Scand 1994;73:313-315

10) Magee KP, Blanco JD, Graham JM, et al:Endometritis after cesarean. Am J Perinatol 1994;11:24-26

11) Cunningham FG, MacDonald PC, Gant NF, et al:Infection and disorders of the puerperium. Williams Obstetrics (Cunningham FG, et al, eds), 20th ed, 1997;p549, Appleton & Lange, Stamford

12) 妊産婦死亡検討委員会: 敗血症による死亡例-日本の母体死亡. 1998; pp208-213, 三宝社, 東京

13) Atrash HK, Koonin LM, Lawson HW, et al:Maternal mortality in the United States, 1979-1986. Obstet Gynecol 1990;76:1055-1060

14) Rochat RW, Koonin LM, Atrash HK, et al:Maternal mortality in the United States:Report from the Maternal Mortality Collaborative. Obstet Gynecol 1988;72:91-97

15) Filker R, Monif GRG:The significance of temperature during the first 24 hours postpartum. Obstet gynecol 1979;53:358-361

16) Sweet RL, Ledger WJ:Puerperal infectious morbidity:A two-year review. Am J Obstet Gynecol 1973;117:1093-1100

17) Maberry MC, Gilstrap LC, Bawdon BE, et al:Anaerobic coverage for intra-amniotic infection:Maternal and perinatal impact. Am J Perinatol 1991;8:338-341

18) Faro S:Soft tissue infections. Infections in Pregnancy (Gilstrap LC, Faro S, eds). 1990;p75, Wiley-Liss, New York

19) Ramin SM, Ramus R, Little B, et al:Early repair of episiotomy dehiscence associated with infection. Am J Obstet Gynecol 1992;167:1104-1107

20) Goldaber KG, Wendel PJ, McIntire DD, et al:Postpartum perineal morbidity after fourth degree perineal repair. Am J Obstet Gynecol 1993;168:489-493

21) Shy KK, Eschenback DA:Fatal perineal cellulitis from an episiotomy site. Obstet Gynecol 1979;54:292-298

22) Finkler NJ, Safon LE, Ryan KJ:Bilateral postpartum vulvar edema associated with maternal death. Am J Obstet Gynecol 1987;156:1188-1189

23) Collins CG, McCallum EA, Nelson EW, et al:Suppurative pelvic thrombophlebitis:A study of 70 patients treated by ligation of the inferior vera cava and ovarian veins. Surgery 1951;30:298-310

24) Duff P, Gibbs RS:Pelvic vein thrombophlebitis:Diagnostic dilemma and therapeutic challenge. Obstet Gynecol Surv 1983;38:365-373

25) Whitfield JW, Valenti WH, Richard MC:Toxic shock syndrome in the puerperium. J A M A 1981;246:1806-1807

26) Jorup-Ronstrom C, Hofling M, Lungberg C, et al:Streptococcal toxic shock syndrome in a post partum woman:Case report and review of the literature. Infection 1996;24:64-67

27) 宇田川秀雄, 幸内公一, 吉野範秀, ほか: A群溶連菌による重大な分娩合併症-妊娠末期の母児死亡3例について. 日本産科婦人科学会雑誌 1997; 49: 125-128

28) 大江健二: 劇症型A群レンサ球菌感染症. モダンメディア 1995; 41: 12-19

29) The Working Group on Severe Streptococcal Infections:Defining the group A streptococcal toxic shock syndrome. J A M A 1993;269:390-391

30) Matheson I, Aursners I, Horgen M, et al:Bacteriological findings and clinical symptoms in relation to clinical outcome in puerperal mastitis. Acta Obstet Gynecol Scand 1988;67:723-726

31) Almeida OD, Kitay DI:Lactation suppression and puerperal fever. Am J Obstet Gynecol 1986;154:940-941

32) Marshall BR, Hepper JK, Zubiel CC:Sporadic puerperal mastitis:An infection that need not interrupt lactation. J A M A 1975;233:1377-1379

33) Niebyl JR, Spence MR, Parmley TH:Sporadic (nonepidemic) puerperal mastitis. J Reprod Med 1978;20:97-100

P.263 掲載の参考文献

1) 喜多正和: 妊娠と免疫. 妊娠とウイルス感染症(今西二郎, 山元貴雄, 編). 1992; pp58-69, 医薬ジャーナル社, 大阪

2) 佐治文隆: ウイルス感染症. 臨床生殖免疫(磯島晋三, 編). 1996; pp105-119, メジカルビュー社, 東京

3) 加地正郎: かぜ症候群. 感染症学-基礎と臨床(上田泰, ほか編). 1984; pp605-612, メジカルビュー社, 東京

4) Engel JP:Viral upper respiratory infections. Semin Respir Infect 1995;10:3-13

5) 松島敏春: 肺炎の分類. 臨床医 1995; 21: 2370-2373

6) 保田仁介: インフルエンザウイルス. 妊娠とウイルス感染症(今西二郎, 山元貴雄, 編). 1992; pp135-137, 医薬ジャーナル社, 大阪

7) 松田静治: 妊娠時に使える抗生物質と使用法の実際. 抗菌薬化学療法(嶋田甚五郎, 砂川慶介, 編). 1992; pp187-197, 文光堂, 東京

8) O'Brien RJ:The treatment of tuberculosis. Tuberculosis (Reichman LB, Hershfield ES, eds). 1993;pp207-240, Dekker, New York

9) 第一製薬(株): 妊娠と肺結核. 結核診療の実際, 改訂版. 1976; pp152-154, アサヒメディカル, 東京

P.269 掲載の参考文献

1) Ueno F, Shibata M:Gastrointestinal and hepatic complications in the pregnant patient. Current Opinion in Critical Care 1997;3:159-164

2) Knox TA, Olans LB:Liver disease in pregnancy. N Engl J Med 1996;335:569-576

3) Mishra L, Seeff LB:Viral hepatitis, A through E, complicating pregnancy. Gastroenterol Clin North Am 1992;21:873-887

4) 三田村圭二, 柴田実: A型・B型急性肝炎. 消化器疾患最新の治療1999-2000(戸田剛太郎, 杉町圭蔵, 中村孝司, 編). 1998; pp251-254, 南江堂, 東京

5) 柴田実: 急性肝不全. Medicina 1998; 35(増刊号): 326-328

6) Simms J, Duff P:Viral hepatitis in pregnancy. Semin Perinatol 1993;17:384-393

7) Dinsmoor MJ:Hepatitis virus in the obstetric patients. Infect Dis Clin North Am 1997;11:77-91

8) Mast EE, Krawczynski K:Hepatitis E:An overview. Annu Rev Med 1996;47:257-266

9) Hussaini SH, Skidmore SJ, Richardson P, et al:Severe hepatitis E infection during pregnancy. J Viral Hepat 1997;4:51-54

10) Rose SR:Pregnancy and travel. Emerg Med Clin North Am 997;15:93-111

11) Kaufman B, Gandhi SA, Louie E, et al:Herpes simplex virus hepatitis:Case report and review. Clin Infect Dis 1997;24:334-338

12) Yaziji H, Hill T, Pitman TC, et al:Gestational herpes simplex virus hepatitis. South Med 1997;90:347-351

13) Klein NA, Mabie WC, Shaver DC, et al:Herpes simplex virus hepatitis in pregnancy:Two patients successfully treated with acyclovir. Gastroenterology 1991;100:239-244

14) Lee WM:Pregnancy in patients with chronic liver disease. Gastroenterol Clin North Am 1992;21:889-903

15) Powell EE, Molloy D:Successful in vitro fertilization and pregnancy in a patient with autoimmune chronic active hepatitis and cirrhosis. J Gastroenterol Hepatol 1995;10:233-235

16) Grange JD, Abergel A, Amiot X, et al:Interactions between chronic viral hepatitis C and Pregnancy, Gastroenterol Clin Biol 1995;19:520-524

17) Pajor A, Lehoczky D:Pregnancy in liver cirrhosis;Assessment of maternal and fetal risks in eleven patients and review of the management. Gynecol Obstet Invest 1994;38:45-50

18) Kochhar R, Goenka MK, Mehta SK:Endoscopic sclerotherapy during pregnancy. Am J Gastroenterol 1990;85:1132-1135

19) Iwase H, Morise K, Kawase T, et al:Endoscopic injection sclerotherapy for esophageal varices during pregnancy. Gastroenterol 1994;18:80-83

20) Stiegmann GV, Goff JS, Michaletz-Onody PA, et al:Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-1532

21) D'Amico G, Pagliaro L, Bosch J:The treatment of portal hypertension:Ameta-analytic review. Hepatology 1995;22:332-354

22) Cello JP:Endoscopic management of esophageal variceal hemorrhage:Injection, banding, Glue, otreotide, or a combination? Semin Gastroitest Dis 1997;8:179-187

23) Rogers RG, Monahan EG:Postoperative hemorrhage due to avulsion of perihepatic adhesions after pneumoperitoneum. J Am Asoc Gynecol Laparosc 1996;3:631-633

24) Singer AJ, Brandt LJ:Pathophysiology of the gastrointestinal tract during Pregnancy. Am J Gasoenterol 1991;86:1695-1712

25) Torbey CF, Richter JE:Gastrointestinal motility disorders in pregnancy. Semin Gastrointest Dis 1995;6:203-216

26) Cappell MS, Colon VJ, Sidhom OA:A study of eight centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal outcome with comparison to control groups. Am J Gastroenterol 1996;91:348-354

27) Gold BD, Khanna B, Huang LM, et al:Helicobacter pylori acquisition in infancy after decline of maternal passive immunity. Pediatr, RO 1997;41:641-646

28) Ashorn M, Miettinen A, Ruuska T, et al:Seroepidemiological study of Helicobacter pylori infection in infancy. Arch Dis Child Fetal Neonatal Ed 1996;74:141-142

29) Epstein FB:Acute abdominal pain in pregnancy. Emerg Med Clin North. 1994;12:151-165

30) Fallon FW, Newman JS, Fallon GL, et al:The surgical management of intra-abdominal inflammatory conditions during pregnancy. Surg Clin North Am 1995;75:15-31

31) Gurbuz AT, Peetz ME:The acute abdomen in the pregnant patient:Is there a role for laparos-copy?Surg Endosc 1997;11:98-102

32) Perdue PW, Johnson HW, Stafford PW:Intestinal obstruction complicating pregnancy. Am J Surg 1992;164:384-388

33) Connolly MM, Unti JA, Nora PF:Bowel obstruction in pregnancy. Surg Clin North Am 1995;75:101-113

34) Ghumman E, Barry M, Grace PA:Management of gallstones in pregnancy. Br J Surg 1997;84:1646-1650

35) Soper NJ, Hunter JG, Petrie RH:Laparoscopic cholecystectomy during pregnancy. Surg En dosc 1992;6:115-117

36) Steinbrook RA, Brooks DC, Datta S:Laparoscopic cholecystectomy during pregnancy:Review of anesthetic management, surgical considerations. Surg En dosc 1996;10:511-515

37) Gouldman JW, Sticca RP, Rippon MB, et al:Laparoscopic cholecystectomy in pregnancy. Am Surg 1998;64:93-97

38) Jamidar PA, Beck GJ, Hoffman BJ, et al:Endoscopic retrograde cholangiopancreatography in Pregnancy. Am J Gastroenterol 1995;90:1263-1267

39) Nesbitt TH, Kay HH, McCoy MC, et al:Endoscopic management of biliary disease during pregnancy. Obstet Gynecol 1996;87:806-809

40) Swisher SG, Hunt KK, Schmit PJ.et al; Management of pancreatitis complicating pregnancy. Am Surg 1994;60:759-762

P.275 掲載の参考文献

1) Schulman A, Herlinger H:Urinary tract dilatation in pregnancy. Br J Radiol 1975;48:638-645

2) Romero R, Oyarzun E, Mazor M, et al:Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol 1989;73:576-582

3) Whalley P:Bacteriuria of pregnancy. Am J Obstet Gynecol 1967;97:723-738

4) Rouse DJ, Andrews WW, Goldenberg RL, et al:Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis:A cost-effectiveness and cost-benefit analysis. Obstet Gynecol 1995;86:119-123

5) Rouse DJ:When to Screen in Obstetrics and Gynecology (Wildschut HIJ, et al, eds). 1996;pp163-169, Saunders, London

6) Gilstrap LC 3d, Hankins GD, Snyder RR, et al:Acute pyelonephritis in pregnancy. Compr Ther 1986;12:38-42

7) Harris RE, Gilstrap LC 3d:Prevention of recurrent pyelonephritis during pregnancy, Obstet Gynecol 1974;44:637-641

8) Van Dorsten JP, Lenke RR, Schifrin BS:Pyelonephritis in pregnancy:The role of in-hospital management and nitrofurantoin suppression. J Reprod Med 1987;32:895-900

P.285 掲載の参考文献

1) 川名尚: 臨床医に必要なウイルス学. 周産期医学 1997; 27: 301-306

2) 加藤茂孝: 風疹ウイルス胎児感染の遺伝子診断. 産婦人科の実際 1994; 43: 19-23

3) 種村光代: 風疹ウイルス母子感染への対応. 周産期医学 1997; 27: 333-337

4) 沼崎啓, 千葉峻三: サイトメガロウイルス. 周産期医学 1997; 27: 338-342

5) 川名尚, 菊池昭彦, 岡井崇, ほか: パルボウイルスB19の母児感染. 周産期医学 1997; 27: 354-358

6) 松永泰子: 伝染性紅斑とヒトパルボウイルスB19. 臨床とウイルス 1995; 23: 99-103

7) Sheikh AU, Ernest JM, O'Shea M:Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol 1992;167:337-341

8) 後藤節子, 杉山正子: B群溶連菌と母児感染. 産婦人科治療 1993; 67: 177-181

P.292 掲載の参考文献

1) 森島恒雄: ウイルス感染症診断の進歩. ウイルス感染症(茂田士郎, 森島恒雄, 編). 1997; pp41-54, 医薬ジャーナル社, 大阪

2) 森島恒雄, 川名尚, 平山宗宏: 新生児ヘルペス全国調査. 日本小児科学会雑誌 1989; 93: 1990-1995

3) Kimura H, Futamura M, Kito H, et al:Detection of viral DNA in neonatal herpes simplex virus infection:Frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991;164:289-293

4) Morishima T:New diagnostic techniques for the management of herpesvirus infections. Herpes 1996;3:5-13

5) Rotbart H:Enteroviruses. Krugman's Infectious Diseases of Children (Katz SL, et al, eds), 10th ed.1998;pp81-97, Mosby, St. Louis

6) Rotbart HA:Diagnosis of enteroviral meningitis with the polymerase chain reaction. J Pediatr 1990;117:85-89

7) 山崎俊夫: 麻疹. 周産期医学 1997; 27: 389-392

8) 川上勝朗: 麻疹ワクチンのsecondary failure. 臨床とウイルス 1994; 22: 251-254

9) 千葉勉: 妊婦のサイトメガロウイルス抗体保有率の低下. 日本臨床 1998; 56: 193-196

10) Morita M, Morishima T, Yamazaki T, et al:Clinical survey of congenital cytomegalovirus infection in Japan. Acta Paediatr Jpn 1998;40:432-436

11) 森島恒雄: 感染症における遺伝子診断-有用性と限界. 小児科診療 1996; 59: 814-820

12) Weber B, Opp H, Born HJ, et al:Laboratory diagnosis of congenital human cytomegalovirus infection using polymerase chain reaction and shell vial culture. Infection 1992;20:155-157

13) Roberts F, Boyer K, McLeod R:Toxoplasmosis. Krugman's Infectious Diseases of Children (Katz SL, et al, eds), 10th ed. 1998;pp538-570, Mosby, St. Louis

14) Hohlfeld P, Daffos T, Costa JM, et al:Prenatal diagnosis of congenital toxoplasmosis with apolymerase-chain reaction test on amniotic fluid. N Engl J Med 1994;331:695-699

P.299 掲載の参考文献

1) 加藤達夫: 予防接種とその事故. 今日の治療方針. 1997; p177, 医学書院, 東京

2) 川名尚, 相田圭子, 小島俊行: 産婦人科関連感染症最新情報-厚生省感染症サーベイランスより. 産婦人科の実際 1998; 47: 299-305

3) 木村三生夫: 予防接種, 一般的な禁忌. ワクチンハンドブック(国立予防衛生研究会学友会, 編). 1994; pp283-301

4) Immunization Practices Advisory Committee/Centers for Disease Control:Rubella vaccination during pregnancy-United States,1971-1988. MMWR 1989;38:289-293

5) Enders G, Miller E, Cradoke-Watson J, et al:Consequence of varicella and herpes zoster in pregnancy, prospective study of 1739 cases. Lancet 1994;343:1547-1550

P.305 掲載の参考文献

1) 加藤茂孝: 風疹ウイルス. ウイルス感染症の診断と病理. 1991; pp133-139, 医学書院, 東京

2) Centers for Disease Control:Rubella and congenital rubella-United States,1983. MMWR 1984;33:237-247
pubmed

3) Rawls WE, Phillips A, Melnick JL, et al:Persistent virus infection in congenital rubella. Arch Ophthalmol 1967;77:430-433

4) 加藤茂孝: 風疹感染の胎児遺伝子診断と先天性障害の発生機序. 産婦人科の実際 1998; 47: 313-320

5) Gregg NM:Congenital cataract following German measles in the mother. Trans Ophthalmol SocA ust 1941;3:35-46

6) Miller E, Cradock-Watson JE, Pollock TM:Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982;ii:781-784

7) 植田浩司, 小野正子: 風疹ワクチンの将来の接種はどうあるべきか. 新・予防接種のすべて. 1997; pp102-107, 診断と治療社, 東京

8) 川名尚, 相田圭子, 小島俊行: 産婦人科関連感染症最新情報-厚生省サーベイランスより. 産婦人科の実際 1998; 47: 299-305

9) 種村光代: 風疹, HSV, CMV, HPV-B19-ウイルス母子感染の遺伝子診断. 産科と婦人科 1997; 64: 1699-1702

10) Tanemura M, Suzumori K, Yagami Y, et al:Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction:A study of 34 cases diagnosed in fetuses. Am J Obstet Gynecol 1996;174:578-582

11) 種村光代: 風疹感染の出生前診断. 産婦人科治療 1995; 71: 71-75

12) 種村光代, 鈴森薫, 八神喜昭: 風疹特異的IgM抗体測定試薬キットの改良による測定値の差に関する検討. 第13回日本産婦人科感染症研究会学術講演会記録集. 1996; pp64-65, 東京

13) Inouye S, Hasegawa A, Matsuno S, et al:Changes in antibody avidity after virus infections:Detection by an immunosorbent assay in which a mild protein-denaturing agent is employed. Clin Microbiol 1984;20:525-529

14) 種村光代, 岡田節男, 鈴森薫, ほか: 母体の風疹IgG親和性と胎児感染の遺伝子診断. 第12回日本産婦人科感染症研究会学術講演会記録集. 1995; pp70-71, 東京

15) Centers for Disease Control:Rubella vaccination during pregnancy-United States, 1971-1986. MMWR 1987;36:457-461

16) 加藤茂孝: 妊婦への風疹ワクチン接種への安全性. 日本医事新報 1989; 3418: 43-45

17) Suzumori K, Iida T, Adachi R, et al:Prenatal diagnosis of rubella infection by fetal blood sampling. Asia Oceania J Obstet Gynaecol 1991;17:113-117

18) Ho-Terry L, Terry GM, Londesborough P:Diagnosis of foetal rubella virus infection by polymerase chain reaction. J Gen Virol 1990;71:1607-1611

P.314 掲載の参考文献

1) 加藤茂孝: 日本における先天性風疹症候群-1978～93年の発生状況. 臨床とウイルス 1995; 23: 148-154

2) 門屋亮, 植田浩司, 福重淳一郎, ほか: 先天性風疹症候群(1981-1992年): 全国聾学校のアンケート調査成績. 臨床とウイルス 1995; 23: 141-147

3) 加藤茂孝, 松永泰子: 風疹. 平成8年度伝染病流行予測調査報告書(厚生省保健医療局結核感染症課, 国立感染症研究所感染症情報センター, 編). 1998; pp81-101, 東京

4) 加藤茂孝, 福島雅夫: 風疹感染の出生前遺伝子診断. 感染症-遺伝子診断と分子疫学(島田馨, 編). 1992; pp290-293, 日本臨牀社, 大阪

5) 加藤茂孝: 風疹感染の胎児遺伝子診断と先天性障害の発生機作. 産婦人科の実際 1998; 47: 313-320

6) Katow S:Induction mechanism of congenital rubella syndrome:Viral genome diagnosis during pregnancy and molecular epidemiology of virus isolates. Interviology 1999 (in press)

7) Tanemura M, Suzumori K, Yagami Y, et al:Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction:A study of 34 cases diagnosed in fetuses. Am J Obstet Gynecol 1996;174:578-582

8) Miller E, Cradock-Watson JE, Pollock TM:Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982;ii:781-784

9) Hedman K, Seppala I:Recent rubella virus infection indicated by a low avidity of specific IgG. J CIin Immunol 1988;8:214-221

10) Frey T:Report of an International Meeting on Rubella Vaccines and Vaccination, 9 August 1993, Glasgow, United Kingdom. Infect Dis 1994;170:507-509

11) 加藤茂孝: 日本における再感染による先天性風疹症候群例の検討. 第13回日本産科婦人科感染症研究会学術講演会記録集. 1996; pp66-67, 東京

12) Best JM, Banatvala JE, Morgan-Capner P, et al:Fetal infection after maternal reinfection with rubella:Criteria for defining reinfection. BMJ 1989;299:773-775

13) Increased in rubella and congenital rubella syndrome-United States, 1988-1990. MMWR 1991;40:93-99

P.320 掲載の参考文献

1) 沼崎啓, 千葉峻三: サイトメガロウイルス感染の診断と児異常. 臨床婦人科産科 1996; 50: 252-255

2) Shen C-Y, Chang S-F, Yen M-S, et al:Cytomegalovirus excretion in pregnant and nonpregnant women. J Clin Microbiol 1993;31:1635-1636

3) Fowler KB, Stagno S, Pass RF, et al:The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl Med 1992;326:663-667

4) Stagno S, Cloud GA:Working parents:The impact of day care and breast-feeding on cytomegalovirus infections in offspring. Proc Natl Acad Sci USA 1994;91:2384-2389

5) Boppana SB, Britt WJ:Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995;171:1115-1121

6) Demmler GJ:Congenital cytomegalovirus infections. Semin Pediatr Infect Dis 1994;5:52-55

7) Stagno S, Reynolds WD, Pass RF, et al:Breast milk and the risk of cytomegalovirus infetion. N Engl J Med 1980;302:1073-1076

8) 沼崎啓, 千葉峻三: 母乳とウイルス感染-サイトメガロウイルス感染. 周産期医学 1996; 26: 555-558

9) Asanuma H, Numazaki K, Nagata N, et al:Role of milk whey in the transmission of human cytomegalovirus infection by breast milk. Microbiol Immunol 1996;40:201-204

10) Numazaki K:Human cytomegalovirus infection of breast milk. FEMS Immunol Med Microbiol 1997;18:91-98

11) Tegtmeier GE:Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med 1989;113:236-245

12) Yeager AS, Grumet FC, Haeigh EB, et al:Prevention of transfusion-acquired cytomegalovirusin new born infants. J Pediatr 1981;98:281-287

13) 千葉峻三: サイトメガロウイルス-新生児とCompromised hostへの輸血. 日本輸血学会雑誌 1995; 41: 535-537

14) Preiksaitis JK, Brown L, Mc Kenzie M:The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988;157:523-

15) 沼崎啓, 千葉峻三: 病院感染対策上, 問題になると予想される感染. 7. サイトメガロウイルス感染. INFECTION CONTROL 1996; 5: 614-618

16) Hagay ZJ, Biran G, Ornoy A, et al:Congenital cytomegalovirus infection:A long-standing problem still seeking a solution. Am J Obstet Gynecol 1996;174:241-245

17) Balcarek KB, Warren W, Smith RJ, et al:Neonatal screening for congenital cytomegalovirus infection by detection of virus in saliva. J Infect Dis 1993;167:1433-1436

18) Whitley RJ, Cloud G, Gruber W, et al:Ganciclovir treatment of symptomatic congenital cytomegalovirus infection:Results of a phase II study. J Infect Dis 1997;175:1080-1086

19) 沼崎啓: サイトメガロウイルス-疾患の種類と関係. 小児科診療 1997; 60: 1817-1822

20) Numazaki K, Chiba S:Current aspects of diagnosis and treatment of cytomegalovirus infectionsin in infants. Clin Diagn Virol 1997;8:169-181

P.329 掲載の参考文献

1) 川名尚: 性器ヘルペス. 新女性医学大系, 第10巻, 女性と感染症. 1999; pp127-137, 中山書店, 東京

2) 森島恒雄, 川名尚, 平山宗宏: 新生児ヘルペス全国調査. 日本小児科学会雑誌 1989; 93: 1770-1995

3) 山崎俊夫, 森島恒雄, 藤井仁, ほか: 我が国における母子感染の実態. 第31回日本新生児学会抄録集. 1995; p173, 横浜

4) Kawana T, Kawagoe K, Takizawa K, et al:Clinical and virologic studies on female genital herpes. Obstet Gynecol 1982;60:456-461

5) Hutto CH, Arvin A, Jacobs R, et al:Intrauterine herpes simplex virus infections. J Pediatr 1987;110:97-101

6) Baldwin S, Whitley RJ:Teratogen Update;Intrauterine herpes simplex virus infection. Teratolog 1989;39:1-10

7) Arvin AM, Heusleigh PA, Prober CG, et al:Failure of antpartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med 1986;315:796-800

8) Prober CG, Corey L, Brown ZA, et al:The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992;15:1031-1038

9) Eldridge R, Andrews E, Tilson H, et al:Pregnancy outcomes following systematic prenatalacyclovir June 1,1984-June 30,1993.f R 1993;42:806-809

10) 1998guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention.f IWR 1998;47:1-111

11) Stray-Pederson B:Acyclovir in late pregnancy to prevent neonatal herpes simplex. Lancet 1990;336:756

12) Brown ZA, Vontver LA, Benedetti J, et al:Effects on infants of a first episode of genital herpesduring pregnancy.N Engl J Med 1987;317:1246-1251

13) Brown ZA, Benedetti J, Ashley R, et al:Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl Med 1991;324:1247-1252

14) Brown ZA, Salke S, Zeh J, et al:The acquisition of herpes simplex virus during pregnancy. N Engl Med 1997;337:509-515

P.338 掲載の参考文献

1) 大林明: 家族性肝硬変症-とくにオーストラリア抗原との関連について. 医学のあゆみ 1971; 76: 595-598

2) 岡田清, 山田哲男: オーストラリア抗原-特に母児間感染について. 産婦人科の世界 1973; 24: 1339-1346

3) 白木和夫, 小田原真理子, 吉原なみ子, ほか: オーストラリア抗原のvertical transmission. 医学のあゆみ 1974; 88: 294-295

4) Schwitzer IL, Dunn AEG, Peters RL, et al:Viral hepatitis B in neonates and infants. Am J Med 1973;55:762-771

5) Okada K, Kamiyama I, Inomata M, et al:e Antigen in mother's serum as an indicator of vertical transmission of HBV. N Engl J Med 1976;294:746-749

6) 白木和夫, 谷本要, 岡田隆好: HBV母児感染の疫学. 肝・胆・膵 1986; 13: 493-501

7)Shiraki K, Yoshihara N. Sakurai M, et al:Acute hepatitis B in infants born to carrier mothers with the antibody to hepatitis B e antigen. J Pediatr 1980;97:768-770

8) Lin HH, Hsu HY, Chang MH, et al:Hepatitis B virus in the colostra of HBeAg-positive carrier mothers. J Pediatr Gastroenterol Nutr 1993;17:207-210

9) Beasley RP, Stevens CE, Shiao IS, et al:Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;ii 1740-741

10) 白木和夫, 桜井迪朗, 衞藤隆, ほか: B型肝炎ウイルスの垂直感染-そのnatural historyと予防. 医学のあゆみ 1981; 118: 536-545

11) Shiraki K, Yoshihara N, Kawana T:Hepatitis B surface antigen and chronic hepatitis in infants born to asymptomatic carrier mothers. Am J Dis Child 1977;131:644-647

12) 衞藤隆, 秦堅佐工, 桜井迪朗, ほか: 垂直感染によりB型肝炎ウイルスキャリアとなった小児の自然経過について. 肝臓 1987; 28: 391-398

13) 白木和夫, 谷本要, 山田一仁, ほか: 劇症肝炎-全国集計小児105例の分析. 小児科 1986; 26: 1-7

14) Shiraki K, Nagata I, Iizuka T, et al:Mother-to-infant infection by hepatitis B virus and its prevention in Japan. In tern Hepatol Comm 1996;5:74-78

15) Shiraki K, Tanimoto K, Yamada K, et al:Cause of failure in prevention of vertical infection by hepatitis B virus. Acta Paediatr Jpn 1986;28:312-316

16) 白木和夫, 谷本要, 岡田隆好, ほか: B型肝炎垂直感染の諸問題. 日本新生児学会雑誌 1988; 24: 7-13

17) Carman WF, Zanetti AR, Karayiannis P, et al:Vaccine-induced escape mutant of hepatitis Bvirus. Lancet 1990;336:325-329

18) Shiraki K:Vertical transmission of hepatitis B virus and its prevention in Japan. Viral Hepatitis and Liver Disease(Nishioka K, et al, eds).1994;pp530-532, Springer-Verlag, Tokyo

19) 白木和夫: B型肝炎母子感染防止対策の追跡調査及び効果判定に関する研究報告書. 平成7年度厚生省心身障害「小児の心身障害・疾患の予防と治療に関する研究」分担研究. 1996; 217-248

20) 白木和夫: 「B型肝炎母子感染防止事業」の改定をめぐって. 日本小児科学会雑誌 1995; 99: 1075-1078

21) 白木和夫, 飯野四郎: 組換えB型肝炎ワクチン(CHO細胞由来, MCI-015)による母子感染予防試験. 小児科臨床 1991; 44: 1241-1252

22) Suzuki H, lino S, Shiraki K, et al:Safety and efficacy of a recombinant yeast-derived pre-S2+S-containing hepatitis B vaccine(TGP-943):Phase 1,2 and 3 clinical testing. Vaccine 1994;12:1090-1096

23) 白木和夫, 松本脩三, 飯野四郎, ほか: 組換え沈降pre-S2抗原含有B型肝炎ワクチン(酵母由来, TGP-943) のB型肝炎ウイルス母子感染予防試験. 小児科臨床 1993; 46: 83-90

24) Huang F-Y, Lee P-1, Lee C-Y, et al:Hepatitis B vaccination in preterm infants. Fetal & Neonatal 1997;77:135-138

P.346 掲載の参考文献

1) 美馬聡昭, 金井博史, 高妻一郎, ほか: 肝疾患における第3世代HCV抗体測定キット(RIA)の臨床的有用性. 医学と薬学 1994; 32: 1307-1313

2) 厚生省非A非B型肝炎血清疫学研究班報告(西岡久壽彌班長). 1990; pp5-11

3) Inaba N, Shimizu K, Shimizu B, et al:A prospective follow-up study demonstrating the vertical transmission of hepatitis C virus. Chiba Med J 1993;69:67-72

4) Hassan NF, Kotkat A:Prevalence of antibodies to hepatitis C virus in pregnant women in Egypt. J Infect Dis 1993;168:248-249

5) Kumar RM:Interspousal and intrafamilial transmission of hepatitis C virus:A myth or a concern? Obstet Gynecol 1998;91:426-431
pubmed

6) 白木和夫, 岡田隆好, 谷本要: 非A非B型肝炎ウイルスの母児感染. 日本臨牀 1988; 46: 2735-2743

7) Inaba N:A study on the vertical transmission of HBsag from HBsag carrier-state women to their infants. A follow-up of 64 cases. Acta Obstet Gynaecol Jpn 1979;31:1862-1870

8) Ohto K, Terazawa S, Sasaki N, et al:The Vertical Transmission of Hepatitis C Virus Collaboration Study Group:Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-750

9) Xiong SH, Okajima Y, Ishikawa K, et al:Vertical transmission of hepatitis C virus:Risk factors and infantile prognosis. J Obstet Gynaecol Res 1998;24:57-61

10) Mitsui T, Iwano K, Masuko K, et al:Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109-1114

P.352 掲載の参考文献

1) Levy R, Weissman A, Blomberg G, et al:Infection by parvovirus B19 during pregnancy:A review. Obstet Gynecol Surv 1997;52:254-259

2) Brown KE, Anderson SM, Young NS:Erythrocyte P antigen:Cellular receptor for B19 parvo-virus. Science 1993;262:114-117

3) Brown KE, Hibbs JR, Gallinella G, et al:Resistence to parvovirus B19 infection due to lack of virus receptor(erythrocyte P antigen). N Engl J Med 1994;330:1192-1196

4) Yaegashi N, Shiraishi H, Takeshita T, et al:Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989;63:2422-2426

5) 八重樫伸生, 岡村州博, 浜崎洋一, ほか: 妊婦における抗パルボウイルス抗体保有状況. 日本産科婦人科学会雑誌 1990; 42: 162-166

6) 松永泰子: 伝染性紅斑とヒトパルボウイルスB19. 臨床とウイルス 1995; 23: 99-102

7) Hall SM, PHLS working party on fifth disease:Prospective study of human parvovirus(B19)infection in pregnancy. Br Med J 1990;300:1166-1170

8) Gillespie SM, Cartter ML, Asch S, et al:Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990;263:2061-2065

9) Schwarz TF, Nerlich A, Roggendorf H, et al:Parvovirus B19 infection in pregnancy. Internat J Exp Clin Chemother 1990;3:219-223

10) Rodis JF, Quinn DL, Gary Gw, et al:Management and outcomes of pregnancies complicated by human B19 parvovirus infection:Aprospective study. Am J Obstet Gynecol 1990;163:1168-1171

11) Adler SP, Manganello A-MA, Koch WC, et al:Risk of human parvovirus B19 infections among school and hospital employees during endemic periods. J Infect Dis 1993;168:361-368

12) Koch WC, Adler SP, Harger J:Intrauterine parvovirus B19 infection may cause an asymptomaticor recurrent postnatal infection. Pediatr Infect Dis J 1993;12:747-750

13) Guidozzi F, Ballot D, Rothberg AD:Human Blg parvovirus infection in an obstetric popula-tion:Aprospective study determining fetal outcome. J Reprod Med 1994;39:36-38

14) Gratacos E, Torres P-J, Vidal J, et al:The incidence of human parvovirus B19 infetion during pregnancy and its impact on perinatal outcome. J Infect Dis 1995;171:1360-1363

15) Skjoldebrand-Sparre L, Fridell E, Nyman M, et al:A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996;75:336-339

16) Conry JA:Perinatal encephalopathy secondary to in utero human parvovirus B-19(HPV)infection. Neurology 1993;43:A346

17) Weiland HT, Vermey-Keers C, Salimans MMM, et al:Parvovirus B19 associated with fetal abnormality. Lancet 1987;i:682-683

18) Tiessen RG, van Elsacker-Niele AMW, Vermeij-Keers C, et al:A fetus with a parvovirus B19 infection and congenital anomalies,, Prenat Diagn 1994;14:173-176

19) Katz VL, McCoy MC, Kuller JA, et al:An association between fetal parvovirus B19 infection and fetal anomalies:A report of two cases. Am J Perinatol 1996;13:43-45

20) Selbing A, Josefsson A, Dahle LO, et al:Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995;345:660-661

21) Ville Y, de Gayffier A, Brivet F, et al:Fetal-maternal hydrops syndrome in human parvovirus infection. Fetal Diagn Ther 1995;10:204-206

22) Knott PD, Welply GAC, Anderson MJ:Serologically proved intrauterine infection with parvovirus.Br Med J 1984;289:1660

23) Zerbini M, Musiani M, Gentilomi G, et al:Symptomatic parvovirus B19 infection of one fetusin a twin pregnancy. Clin Infect Dis 1993;17:262-263

24) Brown KE, Green SW, de Mayolo JA, et al:Congenital anaemia after transplacental B19 parvovirus infection. Lancet 1994;343:895-896

25) Fairley CK, Smoleniec JS, Caul OE, et al:Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995;346:1335-1337

26) Naides SJ, Weiner CP:Antenatal diagnosis and palliative treatment of non-immune hydropsfetalis secondary to fetal parvovirus B19 infection. Prenat Diagn 1989;9:105-114

27) Yaegashi N, Okamura K, Yajima A, et al:The frequency of human parvovirus B19 infection in nonimmune hydrops fetalis.J Perinat Med 1994;22:159-163

P.361 掲載の参考文献

1) Osame M, Usuku K, Izumo S, et al:HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;i:1031-1032

2) Ohba N, Sameshima M, Uehara F, et al:Ocular manifestations in patients infected with human T-lymphotropic virus type 1(HTLV-1). Ophthalmology Today(LN Ferrez de Olive, ed).1988;pp385-386, Elsevier, Amsterdam

3) Takatsuki K, Uchiyama T, Sagawa K, et al:Adult T-cell leukemia in Japan. Topics in Hematology.1977;pp73-77, Excerpta Medica, Amsterdam

4) Poiesz BJ, Ruscetti FW, Gazdar AF, et al:Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;7717415-7419

5) Hinuma Y, Nagata K, Hanaoka M, et al:Adult T-cell leukemia:Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78:6476-6480

6) Yoshida M, Miyoshi I, Hinuma Y, et al:Isolation and characterization of retrovirus from cell line of adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031-2035

7) Miyoshi I, Kubonishi I, Yoshimoto I, et al:Type C virus particles in a cord T-cell line derivedby co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981;294:770-771

8) Hino S, Yamaguchi K, Katamine S, et al:Mother-to-child transmission of human T-cell leukemia virus type 1. Jpn J Cancer Res Gann 1985;76:474-480

9) Nakano S, Ando Y, Saito K, et al:Primary infection of Japanese infants with adult T-cell leukemia-associated retrovirus(ATLV):Evidence for viral transmission from mothers to children. J Infect 1986;12:205-212

10) Kajiyama W, Kashiwagi S, Ikematsu H,et al:Intrafamilial transmission of adult T-cell leukemi avirus.J Infect Dis 1986;154:851-857

11) Tajima K, Tominaga S, Suchi T, et al:Epidemiological analysis of the distribution of antibodyto adult T-cell leukemia-virus-associated antigen:Possible horizontal transmission of adult T-cell leukemia virus. Jpn J Cancer Res Gann 1982;73:893-901

12) Hino S, Kawamichi T, Funakoshi M, et al:Transfusion-mediated spread of the human T-cell leukemia virus in chronic hemodialysis patients in a heavily endemic area, Nagasaki. Jpn J Cancer Res Gann 1984;75:1070-1075

13) Okochi K, Sato H, Hinuma Y:A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion:Seroconversion in recipients. Vox Sang 1984;46:245-253

14) Kinoshita K, Hino S, Amagasaki T, et al:Demonstration of adult T-cell leukemia virus antigenin milk from three sero-positive mothers. Jpn J Cancer Res Gann 1984;75:103-105

15) Taguchi H, Sawada T, Fujino M, et al:Enzyme-linked immunosorbent assay of antibodies toadult T-cell leukemia-associated antibodies. Jpn J Cancer Res Gann 1983;74:185-188

16) Ikeda M, Fujino R, Matsui T, et al:A new agglutination test for serum antibodies to adult T-cellleukemia virus. Jpn J Cancer Res Gann 1984;75:845-848

17) 奥田浩人, 金村真知子, 太田タキ子, ほか: Western blot法による抗ATLA抗体検索の基礎的研究. 臨床検査 1987; 31: 207-210

18) Kinoshita K, Amagasaki T, Hino S, et al:Milk-borne transmission of HTLV-1 from carrier mothers to their children. Jpn J Cancer Res Gann 1987;78:674-680

19) Kusuhara K, Sonoda S, Takahashi K, et al:Mother-to-child transmission of human T-cell leukemia virus type-1(HTLV-1):A fifteen-year follow-up study in Okinawa, Japan.Int J Cancer 1987;40:755-757

20) 一条元彦, 中野司朗, 斉藤謙介, ほか: HTLV-1(Human T-lymphotropic Virus type-1)の母児感染について. 日本産科婦人科学会雑誌 1988; 40: 499-503

21) 沖利貴, 永田行博: HTLV-1母児感染の実態と児栄養法について. 産婦人科の実際 1989; 38: 1527-1533

22) 永田行博, 沖利貴, 吉永光裕: HTLV-1. 産婦人科の実際 1991; 40: 961-968

23) 永田行博, 沖利貴, 吉永光裕, ほか: HTLV-1の母児感染とその予防. 産婦人科の実際 1992; 41: 609-613

24) 永田行博, 沖利貴, 吉永光裕, ほか: HTLV-1の母児感染. 産婦人科の実際 1993; 42: 711-715

25) Takahashi K, Sonoda S, Yashiki S, et al:Protective effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type-1. Jpn Soc Basic Reproduct Immunol 1987;2:46-49

26) Sawada T, Iwahara Y, Isii K, et al:Immunoglobulin prophylaxis against milkborne transmission of human T-cell leukemia virus type 1 in rabbits, J Infect Dis 1991;164:1193-1196

27) Yoshinaga M, Yashiki S, Oki T, et al:Amaternal risk factor for mother-to-child HTLV-1 transmission:Viral antigen-producing capacities in culture of peripheral blood and breast milkcells. Jpn J Cancer Res Gann 1995;86:649-654

28) Ueda K, Kusuhara K, Tokunaga K, et al:Cohort effect on HTLV-1 seroprevalence in southern Japan. Lancet 1989;ii:979

29) Oguma S:Simulation of dynamic changes of human T-cell leukemia virus type 1 carriage rates.Jpn J Cancer Res Gann 1990;81:15-21

30) Kashiwagi S, Kajiyama W, Hayashi J, et al:Antibody to p40tax protein of human T-cell leukemia virus 1 and infectivity. J Infect Dis 1990;161:426-429

31) Sawada T, Tohmatsu J, Ohara T, et al:High risk of mother-to-child transmission of HTLV-1 in p40tax antibody-positive mothers. Jpn J Cancer Res Gann 1989;80:506-508

32) Hino S, Doi H, Yoshikuni H, et al:HTLV-1 carrier mothers with high-titer antibody are at high risk as a source of infection. Jpn J Cancer Res Gann 1987;78:1156-1158

33) Usuku K. Sonoda S, Osame M, et al:HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-1-associated myelopathy:Comparison with adult T-cell leukemia/lymphoma..Ann Neurol 1988;23:S143-S150

34) Sonoda S:Immunogenetic factors involved in the pathogenesis of adult T-cell leukemia and HTLV-1-associated myelopathy. Gann Monogr Cancer Res 1992;39:81-93

P.376 掲載の参考文献

1) AIDS global data. Wkly Epidemiol Rec 1996;71:361-364

2) HIV/AIDS:The global epidemic. Wkly/Epidemiol Rec 1997;72:17-21

3) CDC:HIV/AIDS Surveillance Report. Vol 8, no.2.1996;US Department of Health and Human Services, Public Health Service, Atlanta, Georgia

4) CDC:HIV/AIDS Surveillance Report. Vol 8, no.1.1996;US Department of Health and Human Services, Public Health Service, Atlanta, Georgia

5) The HIV/AIDS situation in mid 1996:Global and regional highlights. UNAIDS Fact Sheet.July 1,1996;Joint United Nations Programme on HIV/AIDS.

6) III International Conference on AIDS in Asia. Abstract.1997

7) Carpenter CCJ, Fischl MA, Hammer SM, et al:Antiretroviral therapy for HIV infection in 1996.Recommendations of an international panel. JAMA 1996;276:146-154

8) Connor E, Sperling RS, Gelber R, et al:Reduction of maternal-infant transmission of human immunodeficiency virus type 1with zidovudine treatment. N Engl J Med 1994;331:1173-1180

9) CDC:Summary of Notifiable Diseases, United State 1996. Vol 45, no.53,10.1997;US Department of Health and Human Services, Atlanta, Georgia

10) Lewis ST, Reynolds-Kohler C, Fox HE, et al:HIV-1 in trophoblastic and villous Hofbauer cells and haematological precursors in eight-week fetuses. Lancet 1990;335:565-568

11) Thiry L, Sprecher-Goldberger S, Jonckheer T, et al:Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet 1985;ii:891-892

12) Blanche S:Plenary Session. X International Conference on AIDS/V STD World Congress 1994

13) Rouzioux C:Prevention of maternal HIV transmission. Practical guidelines. Drugs 1995;49(suppl 1):17-24

14) Holmberg SD, Horsburgh CR Jr, Ward JW, et al:Biologic factors in the sexual transmission of human immunodeficiency virus. J Infect Dis 1989;160:116-125

15) Mofenson LM, Burns DN:Passive immunization to prevent mother-infant transmission of human immunodeficiency virus:Current issues and future directions. Pediatr Infect Dis J 1991;10:456-462

16) Ryder RW, Nsa W, Hassig SE, et al:Perinatal transmission of the human immunodeficiencyvirus type 1 to infants of seropositive women in Zaire. N Engl J Med 1989;320:1637-1642

17) European Collaborative Study:Risk factors for mother-to-child transmission of HIV-1. Lancet 1992;339:1007-1012

18) Mann DJ, et al:AIDS in the World. A Global Report.1992, Harvard

19) CDC:1994 Revised classification system for human immune deficiency virus infection in children under 13 years of age. MMWR 1994;43:1-10

20) Comeau AM, Harris JA, Mclntosh K, et al:Polymerase chain reaction in detecting HIV infection among seropositive infants:Relation to clinical status and age to results of other assays.J AIDS 1992;5:271-278

21) Forsyth BW, Andiman WA,O'Connor T:Development of a prognosis based clinical staging system for infants infected with human immunodeficiency virus. J Pediatr 1996;129:648-655

22) European Collaborative Study:Children born to women with HIV-1 infection:Natural history and risk of transmission. Lancet 1991;337:253-256

23) Blanche S, Tardieu M, Duliege A, et al:Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. AJDC 1990;144:1210-1215CDC:Classification system for human immune deficiency virus(HIV)infection in children under 13 years of age MMWR 1987;36:225-226

24) CDC:Classification system for human immune deficiency virus(HIV)infection in childrennder l 3 years of age.MMWR 1987;36:225-226

25) 相良祐輔, 浅井政房: エイズウイルスキャリアの周産期ケア. 助産婦雑誌 1988; 42: 896

26) 宮澤豊, 岡田清: 産婦人科の立場から. 図説HIV感染症(服部信, 島田馨, 監). 1993; pp186-198, メジカルビュー社, 東京

27) 宮澤豊: HIV感染者の妊娠・分娩管理の実際. 産科と婦人科 1993; 60: 1761-1774

28) 宮澤豊: エイズと小児科臨床-母子間感染・産婦人科の立場から. 小児科臨床 1994; 47: 905-915

29) 宮澤豊, 相良祐輔, 石渡勇: 研修ノート臨時増刊号, 産婦人科のための「エイズ診療マニュアルQ&A」. 日本母性保護産婦人科医会. 1994. 10

30) 秋山和範, 宮澤豊: HIV母子感染の早期診断とその対応-周産期の立場から. Neonatal Care 1994; 7: 845-852

31) 宮澤豊: HIV感染症と妊娠-母子感染ならびに汚染事故予防を中心に. 日本医事新報 1997; 3805: 27-34

32) 宮澤豊: HIV感染妊婦への対応-母子感染の現状と診療体制. カレントクリニカル. 臨床婦人科産科 1997; 51: 653-661

33) 宮澤豊: 特集「HIV感染症に対する総合戦略」, 母子感染 HIV感染症-その予防, 治療と今後の重要ポイント. 内科 1997; 80: 342-348

34) ジョゼフ・R・マシー(木村哲 , 監訳; 宮澤豊, 分担訳): HIV感染症と妊娠. HIV感染症診療マニュアル. 1997; pp256-277, 医学書院MYW, 東京

35) 井村総一: HIV感染母体出生児対策. 小児内科 1989; 21: 1609-1615

36) Minkoff H, deRegt RH, Landesman S, et al:Pneumocystis carinii pneumonia associated with acquired immunodeficiency syndrome in pregnancy:A report of three maternal deaths. Obstet Gynecol 1986;67:284-287

37) CDC:Zidovudine for the prevention of HIV transmission from mother to infant. MMWR 1994;43:16
pubmed

38) Carpenter CC, Fischl MA, Hammer SM, et al:Antiretroviral therapy for HIV Infection in 1997.Updated recommendations of the International AIDS Society USA panel. JAMA 1997;277:1962-1969

39) Kuhn L, et al:Caesarean section minimizes risk of HIV infection. II National Conference on Human Retroviruses and Related Infections 1995.2

40) Villari P, et al:Cesarean section to reduce perinatal transmission of human immunodeficiencyvirus. Current Clinical Trial:2. Jul,1993

41) Kind C:Efrects of zidovudine prophylaxis and elective cesarean section on vertical HIV transmission. XI International Conference on AIDS.1996

42) Biggar JR, Miotti PG, Taha TE, et al:Perinatal intervention trial in Africa:Effect of birth canal cleansing intervention to prevent HIV transmission. Lancet 1996;347:1647-1650

43) Global Programme on AIDS:Consensus statement from the WHO/UNICEF constitution on HIV transmission and breast-feeding. Wkly Epidemiol Rec 1992;67:177-184

44) 宮澤豊: 特集「周産期のリスクマネージメント」, HIV感染者の妊娠・分娩時の危機管理. 周産期医学 1998; 28: 335-340

45) 宮澤豊: 特集「実戦産科手術のPitfalls and Knacks」, HIV感染症例に対する帝王切開術の注意点. 産婦人科の実際 1996; 45: 1751-1758

P.385 掲載の参考文献

1) Feldman S, Huges WT, Daniel CB:Varicella in children with cancer:Seventy-seven cases.Pediatrics 1975;56:388-397

2) Gray GC, Palinkas LA, Kelley PW:Increasing incidence of varicella hospitalizations in United States Army and Navy personnel:Are today's teenagers more susceptible?Should recruits be vaccinated? Pediatrics 1990;86:867-873

3) Mclntosh D, Isaacs D:Varicella zoster virus infection in pregnancy. Arch Dis Child 1993;68:1-2

4) Katz VL, Kuller JA, McMahon MJ, et al:Varicella during pregnancy. Maternal and fetal effects.West J Med 1995;163:446-450

5) Jones KL, Johnson KA, Chambers CD:Offspring of women infected with varicella during pregnancy:A prospective study. Teratology 1994;49:29-32

6) Pastuszak A L, Levy M, Schick B, et al:Outcome after maternal varicella infection in the first 20 weeks of pregnancy.N Engl J Med 1994;330:901-905

7) Straus SE, Ostrove JM, Inchauspe G, et al:NIH conference. Varicella-zoster virus infections.Biology, natural history, treatment, and prevention..Ann Intern Med 1988;108:221-237

8) Preblud SR:Varicella:Complications and costs., Pediatrics 1986;78:728-735

9) Cox SM, Cunningham FG, Luby J:Management of varicella pneumonia complicating pregnancy. Am J Perinatol 1990;7:300-301

10) Qureshi F, Jacques SM:Maternal varicella during Pregnancy:correlation of maternal historyand fetal outcome with placental histopathology. Hum Pathol 1996;27:191-195

11) Smego R Jr, Asperilla MO:Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol 1991;78:1112-1116

12) Broussard RC, Payne DK, George RB:Treatment with acyclovir of varicella pneumonia in pregnancy. Chest 1991;99:1045-1047

13) Grayson ML, Newton-John H:Smoking and varicella pneumonia.J Infect 1988;16:312

14) Brazin SA, Simkovich JW, Johnson WT:Herpes zoster during pregnancy. Obstet Gynecol 1979;53:175-181

15) Enders G, Miller E, Cradock-Watson J, et al:Consequences of varicella and herpes zoster in pregnancy:Prospective study of 1739 cases. Lancet 1994;343:1548-1551

16) Paryani SG, Arvin AM:Intrauterine infection with varicella-zog. ter virus after maternal varicella. N Engl J Med 1986;314:1542-1546

17) Gershon AA, Steinberg SP, Gelb L, et al:Clinical reinfection with varicella-zoster virus. J Infect Dis 1984;149:137-142

18) Kamiya H,Ihara T, Hattori A, et al:Diagnostic skin test reactions with varicella virus antigen and clinical application of the tes.J Infect Dis 1977;136:784-788

19) Enders G:Management of varicella-zoster virus contact and infection in pregnancy using a standardized varicella-zoster ELISA test. Postgrad Med J 1985;61(S4):23-30

20) Hankins GDV, Gilstrap LC, Patterson G:Acyclovir treatment of varicella pneumonia in pregnancy. Crit Care Med 1987;15:336-337

21) Laforet EC, Lynch CL:Multiple congenital defects following maternal varicella:Case report of a case. N Engl J Med 1947;236:534-537

22) Balducci J, Rodis JF, Rosengren S, et al:Pregnancy outcome following first-trimester varicella infection. Obstet Gynecol 1992;79:5-6

23) Higa K, Dan K, Manabe H:Varicella-zoster virus infections during pregnancy:Hypothesis concerning the mechanisms of congenital malformations. Obstet Gynecol 1987;69:214-222

24) Grose C:Congenital varicella-zoster virus infection and the failure to establish virus-specific cell-mediated immunity. Mol Biol Med 1989;6:453-462

25) Lecuru F, Taurelle R, Bernard JP, et al:Varicella zoster virus infection during pregnancy:The limits of prenatal diagnosis. Eur J Obstet Gynecol Reprod Biol 1994;56:67-68

26) Mouly F, Mirlesse V, Meritet JF, et al:Prenatal diagnosis of fetal varicella-zoster virus infection with polymerase chain reaction of amniotic fluid in 107 cases. Am J Obstet Gynecol 1997;177:894-898

27) Pretorius DH, Hayward I, Jones KL, et al:Sonographic evaluation of pregnancies with maternal varicella infection. J Ultrasound Med 1992;11:459-463

28) Meyers JD:Congenital varicella in term infants:Risk reconsidered. J Infect Dis 1974;129:215-217

29) DeNicola LK, Hanshaw JB:Congenital and neonatal varicella.J Pediatr 1979;94:175-176

30) Miller E, Cradock-Watso JE, Ridehalgh MK:Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989;ii:371-373

31) Herrmann KL:Congenital and perinatal varicella. Clin Obstet Gynecol 1982;25:605-609

32) Pons JC, Rozenberg F, Imbert MC, et al:Prenatal diagnosis of second-trimester congenital varicella syndrome. Prenat Diagn 1992;12:975-976

33) Gershon AA:Prevention and treatment of varicella-zoster virus infection. Pediatr Infect Dis J 1984;3:S34-S36

34) Hanngren K, Grandien M, Granstrom G:Effect of zoster immunoglobulin for varicella prophylaxisin the newborn. Scand J Infect Dis 1985;17:343-347

35) Recommendations of the immunization practices advisory committee(ACIP):Varicella-zosterimmune globulin for the prevention of chicken pox. MMWR 1985;33:84-100

36) Prober CG, Gershon AA, Grose C, et al:Consensus:Varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J 1990;9:865-869

37) Webster MH, Smith CS:Congenital abnormalities and maternal herpes zoster. Br Med J 1977;2:1193
pubmed

38) Magliocco AM, Demetrick DJ, Sarnat HB, et al:Varicella embryopathy. Arch Pathol Lab Med 1992;116:181-186

39) Hanshaw JB, Dudgeon JA, Marshall WC:Varicella-zoster infections. Viral Disease of the Fetus and Newborn.1985;pp192-208, WB Saunders, Philadelphia

40) Scott LL, Hollier LM, Dias K:Perinatal herpesvirus infections:Herpes simplex, varicella, and cytomegalovirus. Infect Dis Clin North Am 1997;11:27-53

P.395 掲載の参考文献

1) Thomas BJ, Evans RT, Taylor RD, et al:Early detection of chlamydial inclusions combining the use of cycloheximide-treated McCoy cells and immunofluorescence staining. J Clin Microbiol 1977;6:285-292

2) Evans RT, Taylor RD:Comparison of various McCoy cell treatment procedures used for rdetection of Chlamydia trachomatis. J Clin Microbiol 1979;10:198-201

3) Patton DL, Moore DE, Spadoni LR, et al:Acomparison of the fallopian tube's response to over and silent salpingitis. Obstet Gynecol 1989;73:622-630

4) Pal WH:Silent pelvic inflammatory disease:Is it overstated?Obstet Gynecol 1995;86:32-325

5) 野口昌良: 実験的卵管炎と周囲癒着に関する研究. 産婦人科マイクロサージャリー学会雑誌 1989; 2: 57-61

6) David E, Nancy JB, Harry PD, et al:Observations concerning the microbial etiology of acutesalpingitis. Am J Obstet Gynecol 1994;170:1008-1017

7) 青木功喜, 二神種忠, 中園直樹: 新生児結膜炎の臨床ならびに病原学的研究. 日本眼科学会雑誌 1982; 86: 1076-1080

8) Hammerschlag MR, Roblin PM, Cummings C, et al:Comparison of enzyme immunoassay and culture for diagnosis of chlamydial conjunctivitis and respiratory infections in infants. J Clin Microbiol 1987;25:2306-2308

9) 岡本俊充: Chlamydia感染検出法の検討と新生児Chlamydia産道内感染防止を目的とした妊婦管理に関する研究. 愛知医科大学医学会雑誌 1993; 21: 413-432

10) Munday PE, Porter R, Falder PF, et al:Spontaneous abortion:An infectious aetiology?Br J Obstet Gynaecol 1984;91:1177-1180

11) 後藤真知子, 伊藤誠, 石川洋, ほか: Chlamydia trachomatis感染が原因と考えられた中期流産の一例. 愛知医科大学医学会雑誌 1993; 21: 91-94

12) Dombroski RA, Woodard DS, Harper M, et al:A rabbit model for bacteria-induced preterm pregnancy loss. Am J Obstet Gyynecol 1990;163:1938-1943

13) 内田聡: 女性性器Chlamydia trachomatis感染症による流産に関する臨床的および実験的研究. 愛知医科大学医学会雑誌 1995; 23: 589-608

14) Bruce JD, Carla CB, Larry GB:Amplification of Chlamydia trachomatis DNA by ligase chain reaction. J Clin Microbiol 1993;31:729-731

15) Stella MR, Rimona TB, Ofer L, et al:Simultaneous detection ofthree common sexually transmit-ted agents by polymerase chain reaction. Am J Obstet Gynecol 1994;171:784-790

16) Piura B, Sarov I, Sarov B, et al:Serum IgG and IgA antibodies specific for Chlamydia trachomatis in salpingitis patients as determined by the immunoperoxidase assay. Eur J Epidemiol 1985;1:110-115

17) 岡本俊充, 野口昌良, 中西正美, ほか: Chlamydia trachomatis抗体保有妊婦とその分娩の転帰. 産婦人科の実際 1991; 40: 2269-2272

18) 野口昌良: クラミジア・トラコマティス感染-検査法の評価. 産婦人科の世界 1998; 50: 95-108

19) 高橋敬一, 塩田恭子, 東海久子, ほか: クラミジア抗体検査の特徴と限界に関する臨床的検討. 日本産科婦人科学会雑誌 1994; 46: 925-928

20) 寺尾俊彦: 周産期をめぐるサイトカイン. 日本産科婦人科学会雑誌 1996; 48: 742-750

P.401 掲載の参考文献

1) Lancefield RC:A serological differentiation of specific types of bovine hemolytic streptococcus(group B).J Exp Med 1934;59:441-458

2) Hunolstein C, D'ascenzi S, Wagner B, et al:Immunochemistry of capsular polysaccharide and virulence properties of type VI Streptococcus agalactiae.1nfect Immun 1993;61:1272-1280

3) Kogan G, Brisson JR, Kasper DL, et al:Structural elucidation of novel type VII group B streptococcus capsular polysaccharide by high resolution NMR spectroscopy. Carbohydr Res 1995;277:1-9

4) Kogan G, Uhrin D, Brisson JR, et al:Structural and immunochemical characterization of the type VIII group B streptococcus capsular polysaccharide. J Biol Chem 1996;271:8786-8790

5) 保科清, 門井伸暁, 仁志田博司, ほか: 新生児B群溶連菌(GBS) 感染症の現状. 日本産科婦人科学会雑誌 1994; 46: 497-502

6) Hoshina K and GBS Infection Study Group:Minimization ofthe number of pregnant women tobe treated with preventive procedure against GBS infection by means of antibody measurement.Acta Paediatr Jpn 1997;39:546-549

7) Boyer KM, Gadzala CAL, Kelly PD, et al:Selective intrapartum chemoprophylaxis of neonatalgroup B streptococcal early-onset disease:II Predictive value of prenatal cultures. J Infect Dis 1983;148:802-809

8) Anthony BF, Okada DM, Hobel CJ:Epidemiology of group B Streptococcus:Longitudinal observations during pregnancy. J Infect Dis 1978;137:524-530

9) Baker CJ, Barrett FF, Gordon RC, et al:Suppurative meningitis due to streptococci of Lancefieldgroup B:Astudy of 33 infants. J Pediatr 1973;82:724-729

10) Ablow RC, Driscoll SG, Efrmann EL, et al:A comparison of early-onset group B streptococcalneonatal infection and the respiratory-distress syndrome of the newborn. N Engl J Med 1976;294:65-70

11) Manroe BL, Rosen feld CR, Weinberg AG, et al:The differential leukocyte count in the assessment and outcome of early-onset neonatal group B streptococcal disease. J Pediatr 1977;91:632-637

12) Regan JA, Chao S, James LS:Premature rupture of membranes, preterm delivery, and group B streptococcal colonization of mothers. Am J Obstet Gynecol 1981;141:184-186

13) American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn:Guidelines for prevention of group B streptococcal(GBS)infection by chemoprophylaxis.Pediatrics 1992;90:775-778

14) Hiller SL, Krohn MA, Kiviat NB, et al:Microbiologic causes and neonatal outcomes associated with chorioamnion infection. Am J Obstet Gynecol 1991;165:955-961

15) Paredas A, Wong P, Mason EO Jr, et al:Nosocomial transmission of group B streptococci in a new born nursery. Pediatrics 1977;59:679-682

16) 小林真澄: マウス新生仔におけるB群溶連菌持続保菌の検討. 感染症学雑誌 1992; 66: 297-301

17) Center for Disease Control and Prevention:Prevention of perinatal group B streptococcal disease. MMWR 1996;45(RR-7):1-24

18) American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn:Reviced guidelines for prevention of early-onset group B streptococcal(GBS)in fection.Pediatrics 1997;99:489-496

19) 後藤節子, 杉山正子: B群溶連菌感染症の垂直感染とその予防. 産婦人科治療 1988; 57: 681-686

20) Whitney CG, Plikaytis BD, Gozansky WS, et al:Prevention practices for perinatal group B streptococcal disease:A multi-state survelance analysis. Obstet Gynecol 1997;89:28-32

21) Baker CJ:Immunization to prevent group B streptococcal disease:Victories and vexations. J Infect Dis 1990;161:917-921

22) 門井伸暁, 保科清: 母子感染の最近の話題-B群溶連菌. 周産期医学 1989; 19: 1549-1553

23) 赤松洋, 川上義, 与田仁志, ほか: 15年間49例の新生児B群溶連菌(GBS)感染症の臨床的疫学的検討. 小児科臨床 1994; 47: 1758-1764

24) Amstey MA, Gibbs RS:Is penicillin G a better choice than ampicillin for prophylaxis of neonatal group B Streptococcus infections?Obstet Gynecol 1994;84:1058-1059

25) McDufhe RS Jr, McGregor JA, Gibbs RS:Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B Streptococcuscarriage. Obstet Gynecol 1993;82:487-489

26) Meyn LA, Hiller SL:Ampicillin susceptibilities of vaginal and placental isolates of group B Streptococcus and Escherichia coli obtained between 1992 and 1994. Antimicrob Agents Chemother 1997;41:1173-1174

27) Jeffery HE, Moses Lahra M:Eight-year outcome of universal screening and intrapartum antibioticsfor maternal group B streptococcal carriers. Pediatrics 1998;101:e2

P.413 掲載の参考文献

1) 楠本雅彦, 淵勲: 実地医家のための梅毒の診断と治療-特に妊婦梅毒. 1971, 金原出版, 東京

2) 淵勲: 梅毒. 性感染症(八神嘉昭, 松田静治, 編). 1995; pp12-124, メジカルビュー社, 東京

3) 大阪府環境保健部, 大阪府医師会(編): 平成7年度大阪府における性感染症動態調査概要. 1995; pp20-22

4) 淵勲, 野田起一郎: 梅毒の母子感染-IgM-TPHA測定の意義. 日本性感染症学会誌 1996; 8: 154-160

5) 津上久弥: 梅毒治療の指標としての梅毒IgMの検出. 日本医事新報 1990; 3002: 43-47

6) 淵勲: 梅毒血清反応とその読み方(臨床). 日本性感染症学会誌 1990; 2: 43-49

7) 淵勲: 妊婦梅毒の周産期管理-治療要否の指標としての分画TPHA. 産婦人科の実際 1985; 34: 1063-1065

8) Fuchi I, Noda K:The significance of measuring IgM-TPHA in case of syphilis during pregnancy.Int J Feto-Maternal Med 1990;3:223-228

P.422 掲載の参考文献

1) Remington JS, McLeod RM, Desmonts G:Toxoplasmosis. Infectious Diseases of the Fetus & Newborn Infant (Remington JS, Klein JO, eds),4th ed.1995;pp0140-267, WB Saunders,Philadelphia

2) Suzuki Y, Orellana MA, Schreiber RD, et al:Interferon-r:The major mediator of resistance against Toxoplasma gondii. Science 1988;240:516-518

3) Suzuki Y, Kojima T, Remington JS, et al:IL-4 is protective against development of toxoplasmicencephalitis. J Immunol 1996;157:2564-2569

4) Suzuki Y, Kojima T, Remington JS, et al:Impaired resistance to the development of toxoplasmicencephalitis in interleukin-6-deficient mice. Infect Immun 1997;65:2339-2345

5) Zuber P, Jacquier P:Epidemiologie de la toxoplasmose:Situation au niveau mondial. Schweiz Med Wochenschr 1995;125 (suppl 65):19S-22S

6) 小島俊行, Remington JS, 佐伯えみ, ほか: 妊婦における抗トキソプラズマIgG, IgM抗体保有率とその測定法について. 日本新生児学会雑誌 1998; 34: 420

7) Bowie WR, King AS, Werker DH, et al:Outbreak of toxoplasmosis associated with municipal drinking water. Lancet 1997;350:173-177

8) Montoya JG, Remington JS:Studies on the serodiagnosis of toxoplasmic lymphadenitis. Clin Infect Dis 1995;20:781-789

9) Liesenfeld O, Press C, Jose G, et al:False-positive results in immunoglobulin M (IgM)toxo-plasma antibody tests and importance of confirmatory testing:The Platelia Toxo IgM Test. J Clin Microbiol 1997;35:174-178

10) Wilson M, Remington JS, Clavet C, et al:Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group.J Clin Microbiol 1997;35:3112-3115

11) Lappalainen M, Koskela P, Koskiniemi M, et al:Toxoplasmosis acquired during pregnancy:Improved serodiagnosis based on avidity of IgG.J Infect Dis 1993;167:691-697

12) 小島俊行, 佐藤俊則, 佐伯えみ, ほか: トキソプラズマpersistent IgMの2症例. 第47回日本感染症学会東日本地方会総会/第45回日本化学療法学会東日本支部総会講演抄録集. 1998; p88

13) Grover CM, Thullier P, Remington JS, et al:Rapid prenatal diagnosis of congenital toxoplasma infection by using polymerase chain reaction and amniotic fluid. J CIin Microbiol 1990;28:22972301

14) Hohlfeld P, Daffos F, Costa JM, et al:Prenatal diagnosis of congenital toxoplasmosis with apolymerase-chain-reaction test on amniotic fluid. N Engl Med 1994;331:695-699

15) Johnson JD, Butcher PD, Savva D, et al:Application of the polymerase chain reaction to the diagnosis of human toxoplasmosis.J Infect 1993;26:147-158

16) Pratlong F, Boulot P, Villena I, et al:Antenatal diagnosis of congenital toxoplasmosis:Evaluation of the biological parameters in a cohot of 286 patients. Br J Obstet Gynaecol 1996;103:552-557

17) Boothroyd JC, Kim K, Sibley D, et al:Toxoplasma as a paradigm for the use of genetics in the study of protozoan parasites. Molecular Approach to Parasitology(Boothroyd JC, Komuniecki R,eds).1995;pp211-225, Wiley-Liss, New York

18) 鈴木康弘, 樗沢美香, 牧岡朝夫, ほか: イムノブロット法を用いた先天性トキソプラズマ症の新しい血清診断法. 医学のあゆみ 1990; 154: 595-596

19) Schoondermark-van de Ven E, Melchers W, Camps W, et al:Effectiveness of spiramycin fbrtreatment of congenital Toxoplasma gondii infection in rhesus monkeys. Antimicrob Agents Chemother 1994;38:1930-1936

P.431 掲載の参考文献

1) Yamakawa R, Yamashita Y, Yano A, et al:Congenital toxoplasmosis complicated with central diabetes insipidus in a Down syndrome infant(patient report).Brain Dev 1996;18:75-77

2) 神薗慎太郎, 山下裕史朗, 矢野明彦, ほか: 先天性トキソプラズマ症の1例-PCR法による迅速診断の有用性. 日本新生児学会雑誌 1995; 31: 533-537

3) 糸数直哉, 此元隆雄, 井上忍, ほか: 先天性トキソプラズマ症患児治療後の髄液中に検出されたトキソプラズマ特異的DNA-quantitative competitive PCR法による評価の意義. 脳と発達 1996; 28: 264-266

4) 鈴木保宏, 竹本理, 荒井洋, ほか: 胎盤より確定診断し得た先天性トキソプラズマ症の1例. 脳と発達 1998; 30: 411-416

5) 矢野明彦: トキソプラズマ症の最近の話題. 感染・炎症・免疫 1993; 23: 1-29

6) 矢野明彦: 寄生虫と免疫応答. 臨床免疫学. 1997; pp109-122, 朝倉書店, 東京

7) Yano A, Aosai F, Ohta M, et al:Antigen presentation by Toxoplasma gondii-infected cells to CD4+ proliferative T cells and CD8+ cytotoxic cells. J Parasitol 1989; 75:411-416

8) Yang T-H, Aosai F, Norose K, et al:Enhanced cytotoxicity of IFN-r-producing CD4+ cytotoxic T lymphocytes specific for T. gondii-infected human melanoma cells. J Immmunol 1995;150:290-298

9) He Na, Aosai F, Mun Hye-Seong, et al:Cytokine production assayed by RT-PCR in pregnant mice infected by Toxoplasma gondii as a model of congenital toxoplasmosis. Jpn J Trop Med Hyg 1997;25:59-67

10) Yang T-H, Aosai F, Norose K, et al:Heat shock cognate protein 71-associated peptides function as an epitope for T.gondii-specific CD4+CTL. Microbiol Immunol 1997;41:553-561

11) He N, Aosai F, Luo W, et al:Parasite load and cytokine production in pregnant mice infected by Toxoplasma gondii assayed by quantitative competitive-PCR and RT-PCR. Parasitol Int 1997;49:143-147

12) Yano A, Aosai F, Yang T-H, et al:Correlation between direct binding ability of synthetic T.gondii SAGI peptides to HLA-A2 measured by a sensor for surface plasmon resonance and antigenicity of the peptides for T.gondii-infected cell-specific CTL. Biochem Biophys Res Commun 1997;236:257-261

13) Luo W, Aosai F, Ueda M, et al:Kinetics of changes in parasite load in susceptible and resistant mice infected with an avirulent strain of Toxoplasma gondii by using quantitative competitive PCR. J Parasitol 1997;83:1070-1074

14) Jack SR:Infectious Diseases of the Fetus & Newborn Infant (Jack SR, Jerome OK, eds),4th ed.1995;pp140-267, WB Saunders, Philadelphia

15) Boyer KM:Diagnosis and treatment of congenital toxoplasmosis. Adv Pediatr Infect Dis 1996;11:449-467

16) Norose K, Tokushima T, Yano A:Quantitative polymerase chain reaction in diagnosing oculartoxoplasmosis..Am J Ophthalmol 1996;121:441-442

17) Patrick H, Fernand D, Jean-Marc C, et al:Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain reaction test on amniotic fluid. N Engl J Med 1994;331:695-699

P.440 掲載の参考文献

1) 川名林治(編): 院内感染予防のためのマニュアル, 第5版. 1994, 岩手医科大学

2) 川名林治: 微生物学領域からみた院内感染の問題. 病理と臨床 1995; 13: 1263-1269

3) 川名林治: 院内感染対策委員会のありかた. 臨床医 1997; 23: 1315-1317

4) 川名林治: 院内感染の特異性と感染防止の基本的な考え方. 小児内科 1994; 26: 1631-1635

5) 川名林治(監): 標準微生物学, 第6版. 1996, 医学書院, 東京

6) 川名林治: 病原菌別にみる院内感染の特徴. 看護学雑誌 1993; 57: 786-792

7) 厚生省健康政策局指導課(監): 感染症対策Q&A. 1997, へるす出版, 東京

8) 日本環境感染学会(編): 病院感染防止指針, 第2版. 1995, 南山堂, 東京

9) 川名林治: 第1回～第11回東八幡平シンポジウム-院内感染とその対策を考える, 記録集. 1983-1993

10) 松本慶蔵, 川名林治(司会): シンポジウム: 感染症を見直す-古くて新しい感染症. 日本感染症学会雑誌 1997; 21(臨時増刊): 54-56

11) 川名林治: ウイルスの院内感染や業務感染とその対策. 臨床とウイルス 1995; 23(増刊号): 49-55

12) 川名林治: 在宅医療と感染. 病院感染防止と医療器材(川名林治, 京谷光子, 監; 小林寛伊, 永井勲, 編). 1998; pp31-39, 協和企画, 東京

13) 袋井裕美子, 川名林治, 長沢茂, ほか: 盛岡友愛病院における感染対策, 特に疥癬駆除, 消毒剤の効果判定などを中心に. 第13回日本環境感染学会総会. 1998

14) 川名尚, 橋戸円: 性器ヘルペス. 臨床と微生物 1993; 20(増刊号): 705-712

15) 川名林治(編): 消毒剤Q&A. 1995, 医薬ジャーナル社, 大阪

16) Kawana R, Kitamura T, et al:Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology 1997;195(suppl 2):29-35

17) 厚生省健康政策局指導課(監), 日本感染症学会(編): 院内感染対策テキスト(改訂). 1998, へるす出版, 東京

はじめての方へ

個人／法人会員登録のご案内